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In the mouse HT22 hippocampal cell line and immature primary cortical neurons, excessive 
glutamate treatment results in intracellular cysteine depletion, subsequent glutathione loss and 
the steady accumulation of reactive oxygen species (ROS). This form of oxidative stress 
ultimately leads to cell death. Previous data from our laboratory had shown that delayed and 
persistent activation of extracellular signal-regulated kinases-1/2 (ERK1/2) is associated with 
glutamate induced oxidative toxicity in HT22 cells and immature primary neurons. In addition, 
U0126, a specific inhibitor of the ERK-activating kinase, MEK-1/2, inhibits ERK activation and 
prevents cells death induced by glutamate. However the mechanisms responsible for this chronic 
activation of ERK during oxidative stress have not been well characterized.   
Results from this thesis demonstrated that overexpression of a dominant negative mutant 
of MEK1 blocked glutamate toxicity in transfected HT22 cells. These data confirmed previous 
results and illustrated that ERK1/2 activation is necessary for oxidative toxicity. However 
overexpression of a constitutively active MEK1ERK chimera (LA-MEK1ERK2) that induced 
robust ERK activation and translocation into nucleus did not trigger toxicity in HT22 cells. Thus, 
ERK1/2 phosphorylation and activation is not sufficient for glutamate induced cell oxidative 
toxicity. Activation of ERK1/2 in HT22 cells has a distinct kinetic profile with an initial peak 
occurring between 30 minutes and 1 hour of glutamate treatment and a second peak typically 
emerging after 6 hours. I demonstrate here that the initial phase of ERK1/2 induction is due to 
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activation of metabotropic glutamate receptor type I (mGluRI). ERK1/2 activation by mGluRI 
contributes to an HT22 cell adaptive response to oxidative stress as glutamate induced toxicity is 
enhanced upon pharmacological inhibition of mGluRI. The protective effect of ERK1/2 
activation at early times after glutamate treatment is mediated by a restoration of glutathione 
(GSH) levels that are reduced due to depletion of intracellular cysteine pools. Additional results 
suggest that mGluRI may be involved in regulating mRNA and protein levels of glutamate-
cysteine ligase (GCL), which would lead to enhanced glutathione synthesis. Thus, ERK1/2 
activation by mGluRI protects HT22 cells from oxidative toxicity through upregulation of GCL 
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1.0  INTRODUCTION 
1.1 NEURONAL CELL DEATH 
Neuronal cell death not only plays an important role in the normal development of the nervous 
system but also is involved in many neurodegenerative diseases such as Parkinson’s disease 
(PD), amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, several forms of cerebellar 
degeneration, spinal muscular atrophy, and Alzheimer’s disease (AD) (234). The pathogenesis of 
many neurological diseases is characterized by the gradual loss of neurons in certain regions, 
which result in defects of CNS function such as movement and cognition (205).  
Two distinct mechanisms of cell death have been characterized, i.e. apoptosis and 
necrosis (109). Apoptosis is a carefully controlled cell death process, which keeps the content of 
the dying cell intracellular. It is initiated by both physiological and pathological stimuli. 
However, necrosis is a relatively uncontrolled cell death mode and is generally correlated with 
injury  (205). Table 1 shows a comparison of essential features and mechanisms of apoptosis and 
necrosis. 
Recently, increasing studies have shown that necrosis and apoptosis represent 
morphological expressions of a shared biochemical network through caspase (cysteinyl-aspartate 
protease) -dependent or –independent machinery. Mounting evidence is emerging to support an 
apoptosis-necrosis cell death continuum (149, 264). In this continuum, coexisting apoptotic and 
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necrotic mechanisms induce neuronal death; thus, some of the boundaries between apoptosis and 
necrosis are becoming less well defined.  
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Table 1. Comparison of Necrosis vs Apoptosis.    
Adapted from (62) 
 
Apoptosis                                               Necrosis 
 
Pathological Features  
 
Pattern of death                          Individual cells                                                  Whole groups of cells 
 
Cell shape changes                     Cell shrinkage                                                    Cell swelling and lysis 
 
Plasma membrane changes        Membrane preservation,                                     Early membrane breakdown 
                                                        cell surface blebbing                                     
Organelle changes                     Involution, contraction, “apoptotic bodies”       Organelle swelling and          
disruption                                           
Nuclear changes                        Chromatin condensation and fragmentation       Karyolysis, pyknosis (or                 
karyorrhexis) 
 
DNA breakdown                       Internucleosomal DNA fragmentation, free       Diffuse and random DNA 
                                                        3’-ends                                                              degradation 
Cell degradation                        Phagocytosis without cell infiltration                 Marked inflammation, with    




Causes                                           Developmental/programmed                           Toxins 
                                                   Degenerative changes                                      Massive ischemia                                                            
Growth factor deprivation                                Radiation (high dose) 
                                                      Mild ischemia, radiation, etc. 
 
Cellular processes                         Programmed events                                          Noncoordinated events                                     
                                                      Δ membrane phospholipid asymmetry             Cell membrane rupture 
                                        Organelles preserved/shrunk                             Mitochondrial swelling 
                                                      Energy (ATP) dependence                                 Energy independence 
                                                      Requires protein synthesis                                 No protein synthesis         
requirement 
                                                      Requires new RNA transcription                       No RNA synthesis requirement 
 
 
Molecular Events                         Mitochondrial permeability transition               ATP depletion 
                                                     Mitochondrial cytochrome c release                  Enzymatic digestion 
                                                     Caspase activations                                             Protein denaturation 
                                                     Internucleosomal endonucleases                        Diffuse DNA digestion 
                                                     Transglutaminase activation 




1.1.1 Apoptosis  
The term apoptosis (from Greek: falling off) was not introduced to describe cell death until 1971 
(108). In 1972, Kerr et al., illustrated and compared necrosis with apoptosis in liver cells (109).  
They defined apoptosis as cell death that was not only morphologically distinct from necrosis but 
also possessed distinct biochemical and molecular features. Apoptosis plays an important role in 
early development and growth of normal adult tissues. It is regulated not only by physiological 
stimuli but also induced by various disease conditions (205).  
Apoptosis is also referred to as programmed cell death (PCD) or active cell death (ACD), 
since it requires controlled and pre-programmed gene expression. Also, PCD can occur at a 
precise time during development. Apoptosis has distinctive morphological and biochemical 
characteristics such as cell shrinkage, membrane blebbing, chromatin condensation and DNA 
fragmentation. The earliest indications of apoptotic cell death are morphological alterations 
within the cell such as chromatin condensation, disappearance of the nucleolus, and alterations of 
the cell surface, characterized by the occurrence of blebs. These signs are followed by a 
margination of the chromatin at the inner surface of the nuclear membrane. Eventually the 
activation of a variety of nucleases leads to the fragmentation of DNA. DNA degradation during 
apoptosis generally occurs at two levels: initially high molecular weight fragments are generated 
while at later stages nucleosome-sized DNA fragments appear. This requires a number of 
specific DNases, which are activated specifically during apoptosis. The specific pattern of 
internucleosomal fragmentation of DNA can be used to identify an apoptotic cell. On agarose gel 
electrophoresis, a DNA "ladder," could be seen, which is a large series of electrophoretic bands 
differing from their neighbors in molecular weight of about 180 base pairs. There is no marked 
inflammatory reaction as cytoplasmic condensation is observed in apoptotic cells before they are 
  4
sequestered by phagocytes or surrounding cells. Apoptotic cells do not release damaging 
material to extracellular space and therefore limit death to the apoptotic cell.  
A multi-step pathway is involved in apoptosis. Proteins such as caspases play an essential 
role in apoptosis. Caspases are a group of enzymes with a crucial cysteine residue that can cleave 
other proteins after an aspartic acid residue, a specificity which is unusual among proteases. 
They are apoptosis-specific proteases. There are more than ten members of the caspase family 
that form an apoptotic cascade to execute apoptosis in response to death signal. They are divided 
into two categories: upstream initiator caspases and downstream effector caspases. Initiator 
caspases cleave inactive pro-forms of effector caspases, thereby activating them. For example,  
caspase-9, an initiator, can be activated by the death signals and then cleave procaspase 3 after a 
specific aspartic acid residue into a short form that is the active form of caspase 3 (2). Effector 
caspases such as caspase-3 and caspase-7 in turn cleave other protein substrates within various 
subcellular compartment resulting in the apoptotic process. Caspase-3 (also known as CPP32, 
apopain, YAMA) has been identified as a key mediator of apoptosis in mammalian cells. 
Activated caspase 3 may translocate into the nucleus and cleave substrates such as lamin A and 
DNA fragmentation factor (DFF) 40 and 45 (172).  The active form of DFF have DNAse 
activity. DFF 40 and 45 act on DNA and cause DNA fragmentation and chromatin condensation 
which are the hallmarks of apoptosis (172).  
The importance of caspase 3 during morphogenetic cell death in nervous system is also 
demonstrated through genetic studies. Caspase 3 knockout mice exhibted profound dysfunction 
and aberrant development in the brain such as hyperplasia and disorganized cellular deployment 
(120).  
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Another important family of proteins involved in neuronal apoptosis is the Bcl-2 family 
proteins. Bcl-2 and Bcl-XL are anti-apoptotic proteins; however, Bak, Bim, Bad and Bax are 
pro-apoptotic (172). They modulate apoptosis by influencing cytochrome c release from 
mitochondria. Releasing of cytochrome c into the cytosol activates pro-caspase 9 and then 
initiates unapoptotic cascade. Bcl-2 is a negative regulator of cytochrome c release and therefore 
is anti-apoptotic. Transgenic mice that overexpress Bcl-2 have larger brains resulting from 
decreased apoptosis (150, 263). On the contrary, Bax is a pro-apoptotic Bcl-2 family protein. 
Bax knock-out mice display significantly decreased apoptosis of synapse-bearing neurons whose 
survival are neurotropic factor-dependent (43).  
1.1.2 Necrosis 
Scientific papers mentioning necrosis could be found as early as 1930s. The process of necrosis 
is uncontrolled and passive and does not require energy. Necrosis generally occurs in response to 
acute injury such as that generated by toxic substances and trauma. Necrotic cells swell and 
rupture, releasing their cellular components to the extracellular space and causing inflammation 
to neighboring tissues. The damaging effects of necrosis are even worse in neuronal cells given 
the release of neurotransmitters such as glutamate, which can cause excitotoxic injury to their 
neighbors (131). Morphologically, necrosis is characterized by a disruption of cellular 
membranes and a swelling of the cytoplasm and mitochondria, ending in the complete 
disintegration of organelles. The process terminates with total cell lysis. Biochemical features of 
necrosis include loss of regulation of ion homeostasis, random digestion of DNA and DNA 
fragmentation after lysis. In necrosis, DNA breakdown is more diffuse and random than in 
apoptosis, leading to a "smear" on gel electrophoresis rather than a DNA “ladder”.  
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1.1.3 Cell death and acute and chronic neurological diseases 
Neuronal cell death occurs in neuropathological conditions, both in response to acute injury such 
as stroke and during chronic neurodegenerative diseases. Necrosis and apoptosis may be present 
simultaneously within a damaged region of the brain, and be related to the magnitude of the toxic 
stimuli (91).   
Acute insults such as hypoxia, stroke, trauma, and infection cause harsh, usually focal 
injuries to the central nervous system. In general, such severe injuries to the brain result in rapid 
necrosis in the core regions, although in most cases apoptosis is also observed (91). In addition, 
delayed “secondary” injury occurs in a “penumbra” zone which is the area bordering the most 
severely damaged core of ischemia (61). Blood flow in the penumbra zone is gradually reduced 
to below a functional level but still adequate to sustain morphological integrity for a certain 
period of time, which depends on the extent of residual perfusion (86, 87). Clinically, this 
penumbra zone is usually considered as the most promising target for acute stroke therapy 
because the therapeutic window is extended for several hours (13). Part of cell death in these 
penumbra areas appears to be caspase-mediated and has apoptotic characteristics (174, 189, 
213). Thus, a variety of acute neurological diseases may, in part, also involve apoptotic cell 
death.  
Many inherited or sporadic neurodegenerative diseases can be characterized by 
progressive nervous system dysfunction. These disorders are often associated with atrophy of the 
affected central or peripheral nervous system structures. Defects in these neurons cause them to 
function abnormally, eventually bringing about their death and resulting in cognitive and/or 
motor defects. These disorders have classically been categorized by their clinical symptoms and 
therefore reflect their neuropathologic features.  
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One category of these diseases is known for mainly targeting motor systems, and may 
rarely affect cognition function; and only in later stages of the disease. Amyotrophic lateral 
sclerosis (ALS), Parkinson’s disease (PD), Huntington’s disease (HD), spinobulbar atrophy, and 
the spinocerebellar ataxias are included in this class. The pathoetiology of these disorders is 
predicated upon involvement of spinal motor neurons, corticospinal, striatal, or cerebellar 
neurons (91).  
Another group of diseases is known for predominantly having effects on cognition and 
only partially on motor function. Some common neurodegenerative disorders such as 
Alzheimer’s disease (AD), and certain related disorders, such as Pick’s disease, are in this 
category (91).  
The major neurodegenerative diseases and their affected neurons are summarized in 
Table 2. 
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 Table 2.   Selective neuron losses happen in a variety of neurodegenerative diseases.  
  Adapted from (91) 
 
Neurodegenerative Disorders                              Severely Affected Cells 
 
Amyotrophic lateral sclerosis/                  Spinal motor neurons, corticospinal (layer 5) Betz cells 
Lou Gehrig’s disease  
 
Parkinson’s disease                                   Substantia nigra pars compacta, locus ceruleus, vagus dorsal motor 
nucleus, sympathetic ganglia 
 
Huntington’s disease                                 Caudo-putamen medium spiny interneurons, cortical layers 3, 5,            
and 6 neurons 
 
Olivopontocerebellar atrophy/                    Cerebellar Purkinje cells, dentate nucleus, inferior olive 
spinocerebellar ataxia type 1 
(SCA-1) 
 
Machado-Joseph disease/                            Dentate nucleus, red nucleus, substantia nigra pars compacta, 
spinocerebellar ataxia                                    Purkinje cells, brainstem motor nuclei 
 type 3 (MJD1/SCA-3) 
 












1.2 OXIDATIVE STRESS AND NEURONAL CELL DEATH 
1.2.1 Oxidative stress 
Oxidative stress is defined as conditions under which prooxidants (e.g. free radicals, reactive 
oxygen and reactive nitrogen species) exceed the ability of antioxidant systems to neutralize 
them.  
1.2.2 Oxidative stress and neuronal cell death 
An excess of free radical groups in the body can create a potentially unstable cellular 
environment associated with tissue damage. For instance, oxidative stress can trigger neuronal 
cell death and has been implicated in both acute lesions and chronic neurodegenerative diseases 
(217, 226). Growing evidence from experimental models and human patients studies have 
indicated that oxidative stress plays an important role in ischemia (204), trauma (35), ALS (218), 
PD (74) and AD (165). Investigations of intracellular signal transduction pathway affected by 
oxidative stress is crucial not only for clarification of the pathological basis for cell death in these 
disorders, but also for providing potential therapy strategies (184).  
Superoxide dismutases (SOD) are among the most important cellular defense 
mechanisms fighting against oxidative stress. In normal conditions, cytosolic copper zinc 
superoxide dismutase (Cu/Zn SOD), mitochondrial manganese superoxide dismutase (Mn SOD) 
and iron-containing superoxide dismutase (Fe SOD) are responsible for maintaining low levels 
of intracellular O2- by catalyzing its conversion to oxygen and H2O2 (155). In the nervous system, 
normally, endogenous Cu/Zn SOD is ubiquitously expressed (173). Mutations in the Cu/Zn 
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SOD1 which inhibit its dimerization and enzymatic activity (45) are associated with the 
development of the familial form of ALS (199). Consistent with this, over-expression of Cu/Zn 
SOD in adult transgenic rats show marked neuroprotection from acute and chronic damage such 
as traumatic brain injury (160). Oxidative stress is also involved in PD animal models induced by 
1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropypridine (MPTP) administration. Transgenic mice 
overexpressing cystolic Cu/Zn SOD1 are more resistant to MPTP-induced dopaminergic 
neurotoxicity than wild type mice (188). In addition, selective neuronal NO synthase (nNOS) 
inhibitors prevent neurons against MPTP-induced neurtoxicity and mutant mice that lack the 
nNOS gene (nNOS-/-) are notably more resistant to MPTP-induced neurtoxicity compared with 
the controls (78, 153, 187). 
The role of oxidative stress in the pathology of acute neuronal injury, such as stroke, is 
also well established.  A robust increase in ROS in selective regions of the brain is observed 
shortly after reperfusion of ischemic regions, which leads to neuronal cell death that occurs over 
a short period of time (within days) (111, 156).  As mentioned previously, this form of delayed 
neuronal cell death could be found in the penumbral regions (105). Similarly, acute neuronal 
death induced by potent neurotoxins can involve oxidative stress.  For example, MDMA 
administration in mice induces striatal neuronal cell death that is dependent upon free radical 
formation in affected neurons (23). In addition, a commonly used industrial and household 
biocide, methylisothiozolinone, causes acute cell death in cortical neurons cultures via the 
production of ROS (57).    
Therefore, ROS production and neuronal toxicity are intimately associated with a range 
of chronic and acute neurological disorders.      
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1.2.3 ROS and its metabolism  
Oxidative stress can be generated by the increased production of free radicals and/or decreased 
elimination of free radical molecules. This imbalance leads to the accumulation of oxidative 
molecules that can damage susceptible cells.  
Oxygen containing free radicals such as superoxide (O2-), hydroxyl radical (OH), and 
hydrogen peroxide (H2O2) are referred to as reactive oxygen species (ROS) which has been 
reported to contribute to both necrosis and apoptosis through damaging lipids, proteins and DNA 
(217). ROS can interact with nitrogen containing molecules. For example, O2- reacts with nitric 
oxide (NO.) forming peroxynitrite (ONOO-), a member of the family of reactive nitrogen species 
(RNS) (217). A growing body of evidence has shown that ROS could act as important signaling 
molecules in nearly all cells in the body via oxidation-dependent and reversible changes in 
cellular protein function.  For example, hydrogen peroxide (H2O2) is regarded as a specific 
diffusible signaling molecule functioning in processes of learning and memory (106).  
Collectively, ROS and RNS molecules are necessary for important functions in the cell (44), but 
the accumulation of these molecules in excess is harmful to normal cellular physiological 
function. If this damage is irreversible, then it may cause cellular injury, mutation, cancer, and 
eventually cell demise (223). 
Under normal physiological conditions, ROS are produced as a byproduct of metabolic 
reactions. ROS are generated as a result of energy production in mitochondria (from the electron 
transport chain), as part of an antimicrobial (246) or antiviral (76) response, as well as from 
detoxification reactions performed by the cytochrome P-450 system (27, 208). Environmental 
agents such as ultraviolet light, ionizing radiation, redox chemicals and smoking also lead to 
ROS production. As the principal organel les of oxygen consumption, mitochondria are a 
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significant source of ROS production in the cell.  During oxidative phosphorylation, ATP is 
formed as a result of the transfer of electrons from NADH or FADH2 to O2 by a series of electron 
carriers. Ultimately, O2 is reduced to H2O. This process takes place in mitochondria of 
eukaryotic cells. Although the majority of O2 is reduced to H2O during this procedure, a partial 
reduction of oxygen results in the creation of unstable oxygen radicals that interact with 
molecular oxygen or water to generate ROS.  Cells in cardiac tissue and the nervous system, i.e. 
cardiomyocytes and neurons respectively, have greater energy requirements and a higher 
metabolic rate. Because of increased demands on mitochondrial oxidative phosphorylation, these 
cells consume more oxygen than other cells.  
The production of ROS can be compensated by antioxidants, such as small molecular 
weight dietary supplements, including vitamin E and vitamin C; small molecular weight peptides 
and cofactors, including glutathione (GSH) and pyruvate; and enzymes, including superoxide 
dismutase (SOD), glutathione peroxidase and catalase (223). When cells are in an imbalanced 
state, in which the levels of oxidants exceed the capacity of antioxidants, oxidative damage 
occurs in nuclear and mitochondrial DNA, proteins, and lipids.  
1.3 FUNCTION, METABOLISM AND REGULATION OF GLUTATHIONE   
1.3.1 Function of glutathione  
GSH, an important antioxidant, is a tripeptide comprised of glutamate, cysteine, and glycine. The 
primary biological function of glutathione is to act as a non-enzymatic reducing agent to 
maintain protein cysteine thiol side chains in a reduced state. GSH is also used to prevent 
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oxidative stress in most cells and helps to remove free radicals that can damage normal function 
of DNA, lipid and protein etc. As individuals grow older, GSH levels drop, and the ability to 
detoxify free radicals decreases (195). GSH is found ubiquitously in human body. For example, 
it is found in the liver where it detoxifies harmful substances. GSH is also present in the nervous 
system, blood, lungs and intestinal tract. This powerful antioxidant protects the body from the 
damaging effects of free radicals that may lead to neurodegenerative disease.   
In addition to its powerful antioxidant function, GSH acts as a strong anti-toxin, allowing 
the body to eliminate numerous xenobiotic and carcinogenic chemicals (55). It is essential for 
immune cell-mediated immune reactions (20) and cell proliferation (185). It is critical to the 
maintenance of the integrity of red blood cells (18). In addition, GSH is a  storage and transport 
form of cysteine in cells (55). It is widely recognized that deficiencies in the GSH system lead to 
significant apoptosis and ultimately, morbidity (80).  
1.3.2 Synthesis and metabolism of GSH 
GSH is synthesized in cell by two continuous steps and catalyzed by two enzymes. First, 
glutamate-cysteine ligase (GCL) also known as γ-Glutamylcysteine (γGluCys) synthetase (GCS) 
uses glutamate and cysteine as substrates to generate the dipeptide γGluCys, which is then 
combined with glycine to form GSH by glutathione synthetase (GS) (157) (Fig 1). Both of the 
two reactions are ATP-dependent. The intracellular GSH level is regulated via a negative 


















Figure 1.   The synthesis of glutathione (GSH). 
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Glutathione exists in both reduced form and an oxidized dimer – glutathione disulfide (GSSG) 
form in cells. GSSG typically accounts for only 1-2% of total cellular glutathione. GSH and 
GSSG are reversibly converted to one another by the action of two enzymes. GSH peroxidase 
(GPx) and glutathione reductase (GR) (Fig 2).  
H
2 2
   
        Figure 2.   Switch between reduced GSH and oxidized (GSSG) glutathione. 
During the reactions catalyzed by GPx and GR, glutathione is not consumed but recycled 
(Fig 2). On the other hand, the level of the total intracellular GSH is depleted when the 
glutathione-S-conjugates are formed by glutathione-S-transferases (GST) or when glutathione is 
released outside of cells (55). Glutathione consumed by these processes will be replaced by 
newly synthesized GSH under normal conditions. The reactions catalyzed by GST and γ-
glutamyl transpeptidase (γGT) are generally considered as cell defense systems against oxidative 
stress and xenobiotics. γGT uses extracellular GSH and glutathione conjugates as substrates. 
With this enzyme, the γ-glutamyl moiety from GSH or a glutathione conjugate are transferred 
onto an acceptor molecule, thereby forming the dipeptide CysGly or the CysGly conjugate, 
respectively (158, 233). Ectopeptidases can hydrolyze CysGly to cysteine and glycine, which are 
consequently taken up by cells and serve as precursors for cellular GSH synthesis again (55). 
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1.3.3 Regulation of intracellular GSH 
As mentioned previously, two enzymes catalyze GSH synthesis, i.e. GCL and GS. GCL, the rate-
limiting enzyme in GSH synthesis, is a heterodimer composed of two subunits, GCLM and 
GCLC. GCLC is the catalytic domain, with a molecular weight of 73kDa and is the target for 
GSH feedback inhibition (49). GCLM subunit, with a molecular weight of 31kDa, has 
modulatory or regulatory effects on GCLC. GCLM alone does not exhibit catalytic function (49), 
but enhances the enzyme activity of GCLC by lowering the K(m) for glutamate and increasing 
the K(i) to GSH inhibition (41): i.e. it decreases negative feedback inhibition of GCLC by GSH.  
A variety of chemicals have been suggested to induce glutathione biosynthesis through 
increased transcription of GCL. These compounds include those generating ROS and those 
forming glutathione-conjugates (249). In addition, a large number of conditions are shown to 
regulate intracellular GSH concentration by increasing its synthesis rate. These conditions 
include exposure to heavy metal mercury (252), hyperglycemia (240), heat shock (117), ROS 
such as H2O2 (190), nitric oxide (161) or ROS producing compounds (248). Since GCLC is 
feedback inhibited by GSH, depletion of GSH can lead to a short-term upregulation in GSH 
synthesis. With some limit, a decrease in GSH will result in a temporary rise in the activity of 
pre-existing GCL by lessening the feedback inhibition by GSH, inducing a short-term 
enhancement in GSH synthesis (197). However, increased synthesis of GCL subunits via a 
combination of increased transcription and mRNA stability is the main reason for increased de 
novo synthesis of GSH (139, 260).    
  17
1.4 GLUTATHIONE AND NEUROLOGICAL DISORDERS 
1.4.1 Glutathione in brain 
Compared with other organs the brain is particularly sensitive to the generation of ROS and very 
reliant on detoxification of ROS, since the loss of neurons in adult brain can’t generally be 
compensated by generation of new neurons.  
First of all, the brain uses 20% of the oxygen consumed by the body but constitutes only 
2% of the body weight (55). Thus, during oxidative phosphorylation in brain, there is a potential 
to generate a large quantity of ROS. Secondly, some brain areas contain a high content of iron, 
which can assist the generation of ROS (72). Third, the brain is abundant in lipids with 
unsaturated fatty acids, which are targets for lipid peroxidation (81). Lastly, the brain has only 
low to moderate activities of SOD, catalase and GPx compared to other organs such as liver or 
kidney.  
The concentration of GSH in the brain varies from 1 to 3 mM with astrocytes containing 
higher GSH concentrations than neurons (196). The precursors of GSH can cross blood-brain 
barrier and therefore GSH precursors in the blood can be used for new GSH synthesis in brain 
(58). In addition, some precursors for GSH synthesis in neurons, i.e. CysGly and glutamate, are 
released from astrocytes whose important role in protection against neuronal oxidative stress has 
been demonstrated (15).  
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1.4.2 Glutathione and neurological disorders 
GSH plays multiple roles in the nervous system such as a free radical scavenger, redox 
modulator of iontropic receptor activity, and possible neurotransmitter (55). GSH loss can 
exaggerate oxidative stress and may also increase the levels of excitotoxic molecules. 
Furthermore, GSH depletion is well known to contribute to neurological damage. Decreased 
glutathione levels have been implicated in the pathogenesis of PD (17), AD (251), HD (21), ALS 
(38), cerebral ischemia-reperfusion injury (141) and schizophrenia (219). 
The majority (90%) of total cellular glutathione accumulates within the cytoplasm, with 
the remainder localizes predominantly in mitochondria (194). The mitochondrial pool of GSH 
functions to maintain normal mitochondrial function by keeping protein thiols unoxidized. In 
many cells,   glutathione in the mitochondria is much more important than the larger cytoplasmic 
pool in maintaining cell viability and limiting damage to various potentially toxic treatments 
(254). Following the complete loss of both the mitochondrial and cytoplasmic glutathione, 
cerebellar granule neurons in culture exhibit marked dysfunction and neurotoxicity (254). 
Therefore, neurons have a similar dependence on mitochondrial glutathione as other cell types. 
Loss of GSH in neurons may induce mitochondrial damage and neurological dysfunction such as 
is seen in PD, AD, multiple sclerosis, stroke and ALS (84, 85).       
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1.5 NRF2 AND GLUTATHIONE SYNTHESIS REGULATION 
1.5.1 Phase II detoxification enzymes and antioxidants 
Environmental toxicants and metabolites of xenobiotic chemicals can result in neurodegenerative 
diseases such as PD and AD (171). To defend cells against oxidative insults, various phase II 
detoxification enzymes and antioxidants work together to reduce damage caused by oxidative 
stress (127).  
Biotransforming enzymes are categorized as Phase I and Phase II enzymes, which 
indicate functionalization and conjugation respectively (124, 250). The Phase I enzymes, 
composed mainly of the cytochrome P450 supergene family of enzymes, are called 'activators'. 
By adding single nitrogen or oxygen molecules, they modify their target molecules to facilitate 
their removal as reactive molecules. Conjugation reactions by Phase II enzymes, 'excretors', then 
follow. Phase II reactions generally result in a xenobiotic chemical being converted into a water-
soluble compound that can be removed through the urine or bile (136).  
Many reports indicate that phase II detoxification enzymes and antioxidants genes are 
regulated by an antioxidant responsive element (ARE), which is located within the promoter 
regions of these genes (99). The genes driven by ARE include GST A1, GST P1, NQ01, 
Glutamate-cysteine ligase (GCL), ferritin-L, metalloththionein-1, and UDP-glucuronyl 
transferase (UGT).  
Many factors have been suggested to regulate ARE activity. NF-E2-related factor2 
(Nrf2), belonging to the basic leucine zipper family of proteins, serves as one of the most 
important ones. Nrf2, a transcriptional factor, was first identified in 1994 (162) and then 
illustrated to regulate ARE activation in NQ01 in 1996 (243). Interestingly, Nrf2 is also found to 
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bind the ARE of GCL (163) and transcriptionally upregulate the basal and inducible GCL 
subunit genes (99, 101, 247).  
1.5.2 Roles of Nrf2 in defense against oxidative stress 
A variety of antioxidant and detoxification enzymes are positively regulated by the ARE 
sequence, including Nrf2 which serves as a regulator of the ARE-driven cellular protection 
system against ROS and electrophiles. Consistent with this, numerous studies have shown that 
Nrf2 protects many cell types and organ systems from a broad spectrum of toxic insults through 
both known ARE-driven genes and novel cell type-specific genes (128). Specifically, Nrf2 plays 
an important role in protecting cells against various toxins in lung (191), liver (28), GI tract (59) 
and nervous system (48).  
A large body of evidence indicates that oxidative stress is a prominent pathological 
feature in many neurodegenerative diseases, including ALS, AD, and PD. More recently, the 
Nrf2-ARE signaling pathway is considered as a promising drug target to combat oxidative stress 
in neurodegenerative disorders (242).  
1.5.3 Signaling pathways regulating Nrf2 activation 
The molecular mechanism and signaling pathways that regulate the activation of Nrf2 have been 
the subject of considerable investigation for many years. Kelch repeat family proteins, such as 
Keap1 in mouse, sequester Nrf2 within cytoplasm (100) and affect its turnover (115, 210). Nrf2 
turns over rapidly via the ubiquitin-26S proteasome protein degradation system (210) with a 
short half-life from 15 min (170) to 3 h (227). Keap1 is known as a repressor protein for Nrf2 
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since Keap1 directly binds to Nrf2 and prevents its nuclear accumulation. Oxidative stress and 
electrophilic agents antagonize Keap1 inhibition of Nrf2 activity in vivo so that Nrf2 
accumulates within the nucleus and regulates the transcription of genes encoding detoxification 
and antioxidant enzymes by binding to their AREs (100). Interestingly, several groups have in 
parallel indicated that Keap1 functions as an adaptor that bridges Nrf2 to Cullin 3 (cul3)-based 
E3 ligase (39, 68, 114, 227, 265). Thus, Keap1 negatively regulates Nrf2 stability in part by 
targeting Nrf2 for ubiquitination by the cul3 and subsequent degradation by the proteasome 
pathway. Under oxidative stress and electrophiles, the Keap1-mediated Nrf2 degradation 
pathway is impaired, so that the de novo synthesized Nrf2 does not accumulate within the 
nucleus (115).  
1.5.4 Regulation of Nrf2 activation 
Nrf2 activation is regulated by several factors such as transcription, intracellular localization and 
protein stability. For example, CBP and p300 were shown to mediate Nrf2 transactivation (107, 
266). This thesis will focus on one important mechanism of Nrf2 regulation, protein stability. 
Some inducers of ARE-dependent genes do not affect the mRNA levels of Nrf2 while 
leading to an overall increase of Nrf2 protein levels (98, 170, 227, 247). These data indicate that 
posttranscriptional mechanisms play a crucial role in regulating Nrf2 activity. Further 
experiments also showed that the half-life of Nrf2 was prolonged in cells exposed to the same 
inducers, which supported the conclusion that increases in the stability of Nrf2 results in its 
accumulation within the nucleus. In addition, oxidative stress has been found to activate Nrf2 
through effects on its protein stability (170, 227). Specifically, proteasome inhibitors were used 
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to show a decreased degradation of Nrf2 by the ubiquitin-dependent proteasome pathway. 
Collectively, stabilization of Nrf2 is sufficient to induce its nuclear accumulation (171).  
Protein phosphorylation has also been believed to regulate the stability of Nrf2 protein. 
The protein phosphatase inhibitor okadaic acid results in accumulation of Nrf2 in HepG2 cells 
treated with tBHQ (an ARE inducer) (170). It has been reported that the mitogen activated 
protein kinases (MAPK) signaling pathway may also be involved in the regulation of the ARE 
response (261, 262). The MAPK family members and pathway will be defined and discussed in 
next section. For example, the extracellular signal-regulated kinase (ERK) pathway inhibitor, 
PD98059 or U0126 attenuates the inducing effects of tBHQ on Nrf2 protein levels (170). In 
addition, inhibitors of the ERK signaling pathway abolished Nrf2 phosphorylation under hypoxic 
stimuli (179). ERK-directed phosphorylation is required for Nrf2 nuclear translocation during 
PDTC induced GCLM gene expression (267). In general, phosphorylation by the MAPK/ERK 
pathway increases Nrf2 stability (170) which may contribute to the upregulation of GCLC and 
GCLM (267).  
A model has been proposed in which xenobiotics (BHA, tBHQ, GTP, EGCG, PEITC, 
sulforaphane) activate the MAPK pathway via an electrophilic-mediated stress response, leading 
to the transcriptional activation of Nrf2/Maf heterodimers on ARE/EpRE enhancers. The 
subsequent induction of cellular defense/detoxifying genes including Phase II enzymes, may then 
protect cells against toxic insults and thereby enhance cell survival (118).  
PKC is the only kinase that has been shown to directly phosphorylate Nrf2 in vitro (95). 
Although MAPK-dependent phosphorylation may be required for Nrf2 nuclear translocation, 
results from several groups suggest that it is unlikely that Nrf2 itself is a direct target for MAPK 
phosphorylation (214, 267). Mutation of the conserved MAPK consensus phosphorylation sites 
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in Nrf2 did not alter Nrf2 transactivation of GCLM gene expression or Nrf2 interaction with the 




Figure 3.   The simplified mechanisms that can activate Nrf2.  
Adapted from (224) 
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1.6 MITOGEN ACTIVATED PROTEIN KINASES (MAPKS)  
1.6.1 MAPKs members 
The MAPK family members include extracellular signal-regulated kinase (ERK), stress-activated 
protein kinase/N-terminal Jun Kinase (SAPK/JNK) and p38 MAPK. All of them have been 
involved in neuronal injury and disorders (14, 31, 258). 
MAPKs are activated upon dual phosphorylation at specific tyrosine and threonine 
residues by upstream MAPK kinases, which in turn are phosphorylated and activated by MAPK 
kinase kinases such as Raf. In particular, ERK1 and ERK2, which are activated by the 
MAPK/ERK kinase-1/2 (MEK1/2), are emerging as important regulators of neuronal responses 
to both functional (learning and memory) (229) and pathologic stimuli (176). 
MAPKs are multi-functional signal transducing kinases that are involved in many facets 
of cellular regulation including gene expression, cell proliferation, cell survival and cell death 
(182). MAPKs are activated not only by growth factors but also by stresses such as oxidative 
stress, heat shock, genotoxins, UV irradiation and inflammatory cytokines (123). 
1.6.2 MAPKs and neuronal toxicity 
The functions of individual MAPK family members in the brain are diverse. Traditionally, 
specific MAPK family members such as JNK and p38 MAPK have been associated with 
neuronal cell death while ERK has been linked to neuronal cell survival. The balance of 
activation between p38 / JNK and ERK oppose each other to determine whether cells die or 
survive (255).  
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However, individual MAPKs do not function exclusively as pro-death or pro-survival 
factors as a variety of recent papers have demonstrated a role for ERK1/2 in neuronal cell death. 
Furthermore, recent reports have illustrated a crucial protective role of both p38 (125) and JNK 
(7) in a variety of models. However, the activation of ERK1/2 contributes to neuronal survival in 
serum-starved neuronal cultures (255), in an in vivo animal model of hypoxia-ischemia (82) and 
in the brain-derived neurotrophic factor (BDNF) -mediated protection of camptothecin-induced 
cortical neuronal toxicity (90). Model systems such as glutamate-induced oxidative stress (133, 
207, 226), zinc toxicity (212), Fe / ß-amyloid toxicity (122), focal ischemia (4, 175), brain 
trauma (166), seizure-induced neurotoxicity (168), 6-hydroxydopamine toxicity (121), 
methylisothiazolinone insults (57), and okadaic acid (OA) toxicity (202) have all exhibited ERK 
dependent neuronal toxicity. ERK activation not only promotes neuronal toxicity but also cell 
death in other cell types such as astrocytes, oligodendroglia, vascular smooth muscle, fibroblasts 
and renal epithelial cells (34). 
1.7  ERK AND NEURONAL OXIDATIVE TOXICITY  
ERK-1 and ERK-2 (ERK1/2) are two closely related isoforms of the MAPK family. Various 
reports indicate that ERK signaling, in addition to its classical involvement in proliferation, 
differentiation (209), learning and memory (256) and cell survival (46), can also promote 
neuronal cell death and be involved in the pathogenesis of neurodegenerative diseases such as 
AD and PD (34). For example, oxidative toxicity could be blocked upon inhibition of ERK1/2 
activation in a neuronal cell line and primary immature neuron cultures (207, 226). Furthermore, 
in animal models of stroke, a block of ERK1/2 activation by intravenous injection of U0126, an 
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inhibitor of the ERK1/2 activator MEK-1, protects against neuronal cell damage after forebrain 
ischemia and focal cerebral ischemia (169).  
It is interesting to note that the role of ERK1/2 can be different even within the same cell 
type, since activation of ERK1/2 protects HT22 cells from serum withdrawal, but not from 
glutamate-induced oxidative toxicity (200, 226).  The divergent roles of ERK1/2 in various 
neurotoxicity models are likely because of the heterogeneity in the temporal and spatial pattern 
of ERK1/2 activation. Increasing evidence suggests that kinetics, intensity and duration of 
ERK1/2 activation, as well as its subcellular localization, may determine whether downstream 
targets will trigger beneficial or detrimental effects on neuronal cells (34, 36). Specifically, it has 
been suggested that persistent nuclear retention of active phosphorylated-ERK1/2 (p-ERK1/2) is 
associated with glutamate-induced oxidative toxicity (225). In PC12 cells, prolonged nerve 
growth factor (NGF) -induced differentiation is characterized by a more prolonged, persistent 
accumulation of ERK within nuclei; however, rapid and transient epidermal growth factor 
(EGF)-induced proliferation causes a brief activation of ERK without translocation into nuclei 
(148).   
ERK1 (44 kDa) and ERK2 (42 kDa) appear to be similarly regulated in most conditions. 
It is difficult to distinguish the functions of ERK1 from ERK2 with pharmacological methods, 
because of the absence of specific ERK1 or ERK2 inhibitors (e.g. MEK1/2 inhibitors such as 
PD98059 and U0126 inhibit phosphorylation of ERK1 and 2 to comparable levels). 
Nevertheless, gene knockout mice exhibit obviously different phenotypes. ERK1-deficient mice 
are viable, fertile, and normal in size.  However, ERK1 is implicated with a specific role in the 
development of thymocytes, as the number of mature thymocytes was decreased to half in the 
ERK1-deficient mice (178). Furthermore, ERK1-deficient mice show enhanced synaptic 
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plasticity and learning in striatal-mediated tasks (154), but not in those that are hippocampal- or 
amydgala-dependent (211).  On the contrary, ERK2-deficient mice are embryonic lethal, 
indicating that ERK2 is more vital for embryonic development and that ERK1 could not 
compensate for the absence of ERK2 during development (154).  
The clearly identified nuclear targets of ERK1/2 have remained fairly limited.  Most 
identified targets are transcription factors, such as CREB, Elk-1, and the AP-1 complex, 
emphasizing the importance of active ERK1/2 translocation into the nucleus. In addition, ERK 
may affect transcription indirectly via the activation of cytoplasmic targets, such as p90 
ribosomal S6 kinase (RSK), that translocate into the nucleus and activate transcription factors 
such as estrogen receptor, c-Fos, and CREB (65).  
1.8 GLUTAMATE-INDUCED HT22 CELL TOXICITY 
1.8.1 Experimental model   
Extracellular glutamate acts on neurons via several pathways that include binding to ionotropic 
receptors (i.e. kainate, AMPA, and NMDA receptors), metabotropic receptors (mGluRs), high 
affinity glutamate uptake transporters, and a chloride-dependent antiporter (Xc-).   
The Xc- is ubiquitously expressed in mammalian cells. Extracellular cystine is imported 
via Xc- in exchange for intracellular glutamate (206). Cystine is rapidly converted to cysteine in 
the cytoplasm and used as precursor for protein and GSH synthesis as described above. 
Intracellular glutamate concentrations are higher inside than outside the cell. Thus, there is a 
steady and strong concentration gradient that drives this exchange. Due to the low solubility of 
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cystine (the lowest of all common amino acids) and its propensity to undergo thiol-disulfide 
exchange reaction with proteins, the intracellular concentration of cystine is very low (97). 
Intracellular cysteine concentrations are dependent upon the activity of the Xc- exchanger, and 
free cysteine is an important precursor for glutathione synthesis. Therefore the activity of the Xc- 
exchanger directly regulates glutathione levels in the cell, and inhibition of the exchanger, by 
increasing extracellular glutamate, leads to the depletion of intracellular glutathione (167).  
While both neurons and astrocytes express and utilize the Xc- system, there are no reported 
differences in the efficiency of this system between the two cell types (5).         
In this project, glutamate-induced HT22 cell toxicity is used as experimental model. 
HT22 cells, derived from mouse hippocampus, lack ionotropic glutamate receptors. Therefore 
glutamate treatment of these cells leads to cell death through oxidative stress, but not 
excitotoxity (230). Oxidative glutamate toxicity is induced by inhibition of cystine uptake into 
cells, leading to depletion of intracellular cystine and the reduction of GSH. With the decreasing 
supply of GSH, there is a buildup of excessive amounts of ROS in cells (230).  
HT22 cells have been used as a neuronal cell line for the study of glutamate-induced 
oxidative toxicity for more than ten years, but the signaling pathway that causes toxicity in these 
cells remains controversial.  5mM glutamate can induce HT22 cell death in several hours. 
Following glutamate treatment in HT22 cells, activation of 12-lipoxygenase (12-LOX), influx of 
Ca2+ into the cells and subsequent ROS accumulation have been demonstrated (135). The 
characteristics of the Ca2+ channels that are involved in Ca2+ influx are not clear. Several other 
studies have revealed that glutamate-induced oxidative toxicity is dependent upon the activation 
of the phospholipase C (PLC) isoform phosphatidylcholine-specific PLC (PS-PLC) and protein 
kinase C (PKC) (134, 143).  In addition, it has been found that multiple MAPK members are 
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involved in toxicity and that ERK may play a protective role (143). However, data from our 
group suggests that the establishment of glutamate-induced oxidative toxicity depends 
specifically upon the persistent activation of ERK1/2 (226). The pro-death role of ERK has been 
replicated in both HT22 cells and in immature primary cortical cultures (133, 207, 225, 226).  
Thus MEK inhibitors such as U0126 protect both HT22 cells and primary cortical neurons from 
oxidative toxicity and ERK translocation into nuclei. The exact downstream targets of ERK1/2 
activation that are required for oxidative toxicity have not been clarified.   
1.8.2 Oxytosis 
Extensive research studies have suggested that glutamate-induced cell death pathway in HT22 
cells or primary cortical culture is clearly distinct from classical apoptosis or necrosis. The 
unique form of programmed neuronal cell death resulted from oxidative stress and ROS 
accumulation is therefore named oxytosis (231).  
Morphologically, oxidative glutamate toxicity has some of the features of apoptosis such 
as the requirement for macromolecular synthesis, but it lacks the hallmarks of apoptosis, such as 
DNA fragmentation and chromatin condensation (231). At the ultrastructural level, in cells under 
oxytosis, nuclei remain intact with minimal swelling or chromatin condensation. More 
ultrastructural changes are found in cytoplasm. For example, both inner and outer mitochondria 
membranes are swollen and cristae are lost. Golgi bodies and endoplasmic reticulum (ER) also 
appear swollen (232). While in apoptosis cells, intracellular organelles shrink.  
Although glutamate-induced neuronal toxicity has some necrotic morphological features, 
biochemically it resembles some features of apoptosis. For example, macromolecule synthesis is 
required and selective caspase/protease inhibitors such as Ac-YVAD-CMK, TLCK and TPCK 
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protect cells from death (232). However, caspase 3 is not activated and involved in glutamate 
induced neuronal toxicity whereas it is a common feature for apoptosis (232).  
Oxytosis may occur by a series of sequential steps: a loss in GSH levels, an increase in 
the production of ROS and a vast influx of Ca++ which occurs shortly before cell death. Other 
factors such as macromoleular synthesis, lipoxygenase activation, soluble guanylyl cyclase 
(sGC) activation and cGMP production may also be involved. 
1.9 METABOTROPIC GLUTAMATE RECEPTORS AND NEURONAL CELL 
TOXICITY 
1.9.1 Members of the mGluRs 
Glutamate receptors are composed of two major superfamilies: the ligand-gated ion-channel 
ionotropic receptors, and the metabotropic glutamate receptors (mGluRs). mGluRs, with seven 
transmembrane domains, are coupled to effector systems through GTP binding proteins (G-
Protein). Based on sequence similarity, signal transduction, and pharmacology, the mGluRs are 
further subdivided into three groups, i.e. Group I, II and III mGluRs (37). The mGluRs belong to 
a family of G protein-coupled receptors (GPCRs).  
Group I (mGluRI) consists of mGluRs 1 and 5, and is positively coupled to 
phosphoinositide hydrolysis via Gq/G11 (60). The first mGluR, which is known as mGluR1a, 
was cloned and expressed (93, 152) in 1991. Group II, consisting of mGluRs 2 and 3, and group 
III, composed of mGluRs 4, 6, 7 and 8 are both negatively coupled via Gi to adenylate cyclase 
(AC) activity. DmGluRA has been cloned from Drosophila melanogaster. This metabotropic 
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glutamate receptor shows a high homology with the mammalian group II mGluRs, and therefore 
is considered in group II. The existence of multiple isoforms resulting from the alternative 
splicing of the mGluR genes has been demonstrated during the process of molecular cloning.  
mGluRs are widely distributed in mammalian central nervous systems including in the 
hippocampus, basal ganglia (201), Purkinje cells in cerebellum (113) and even in the visual 
system (71). Astrocytes are also reported to express certain subtypes of mGluRs (9). In this 
project, we study HT22 cells which express mGluR1 and 5, but not 2 or 3 (203).  
1.9.2 Structure of mGluRs 
mGluRs have a N-terminal extracellular domain, seven transmembrane domains (TMDs) 
separated by short intra- and extracellular loops, and a cytoplasmic C-terminal domain. Their N-
terminal extracellular domains are relatively large compared to other GPCRs. 
Several amino acids i.e. Arg78, Arg106, Ser165 and Thr188 in the N-terminus are 
responsible for glutamate reorganization. This region is predicted to form a two-globular binding 
pocket for glutamate. There is a cysteine rich domain between thre N-terminal loop and TMDs, 
whose function is not fully resolved. However, this cysteine rich domain may be involved in 
maintaining three dimensional structure or intramolecular transduction (37, 88). Cys140 and 
possibly with Cys67 and Cys109 are important for receptor dimerization (239). Certain residues 
on the intracellular loop of TMDs are critical for the G protein binding. The intracellular C-
terminal domain has the phosphorylation sites and regions that interact with other proteins (37, 
88). Growing evidence also supports that different regions of the mGluR1 are involved in the 
functional activation of distinct effector responses (88).    
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1.9.3 Signal transduction pathway of mGluRs 
The signal transduction pathway of mGluRs has not been fully clarified as of yet. Here we take 
mGluRI as an example. Functional activation of the phospholipase C (PLC)/ inositol 1,4,5-
trisphosphate (IP3) /Ca++ pathway or PLC/ protein kinase C (PKC) is always detected after 
mGluRIs activation. Additional coupling to other transduction pathways is dependent on the 
system in which the mGluRIs have been characterized. Stimulation of cAMP formation through 
AC has also been reported for mGluR1 in several cell types such as CHO cells (8), BHK (baby 
hamster kidney) cells (235),  and human embryonic kidney 293 cells (69, 180). A similar effect 
of mGluR5 has also been reported in LLC-PK1 cells (103) but not in CHO cells (1). Further 
studies have also shown that mGluRI mediated stimulation of AC and PLC are regulated 
independently rather than at different stages on the same pathway (88). In addition to PLC and 
AC pathways, mGluRIs are also believed to affect certain cation channels. For example, in 
cultured primary striatal neurons, mGluRI up-regulates CREB phosphorylation via the 
intracellular Ca2+ release-induced activation of L-type Ca2+ channels (147). In cerebellar granule 
cells, activation of mGluRIs inhibits TASK and TREK type K+ channels (29). Moreover, the 
potential for alternative coupling with other intracellular signaling cascades such as ERK in 
MAPK (19, 77), PLA2 (8) and PLD (112) has been widely documented. The signal transduction 
pathway of mGluRI has been illustrated in Fig 4. 
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 Figure 4.   Signal transduction pathways activated by the mGluR1a through coupling to different G-
proteins. 
    Adapted from (88) 
ER: endoplasmic reticulum 
PLA2: phospholipase A2
PLD: phospholipase D 
DAG: diacylglycerol 
PKA: cAMP-dependent protein kinase 
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1.9.4 mGluRs and neuronal cell death 
Due to the ubiquitous distribution of glutamatergic synapses, mGluRs have the potential to 
participate in a wide range of function of CNS. mGluRs have been implicated in a variety of 
physiological functions, including neurotransmission, long-term potentiation (LTP), and 
reciprocal interactions with the ionotropic glutamate receptors (37).  
mGluRs-mediated neuroprotection against a variety of insults is well established in the 
literature, and each of the subgroups has been documented to provide neuroprotection (62). They 
have been shown to be involved in neurotoxic insults, spinal cord injury, ischemia, epilepsy, 
multiple sclerosis, amyotrophic lateral sclerosis and more recently oxidative stress and diabetes 
(222).  
For instance, due to mGluRs’ role in the motor circuit, their ligands may contribute to 
alleviation of some motor dysfunctions in ALS, HD, PD and cerebellar ataxia (37). As certain 
mGluRs in thalamic and spinal cord neurons are responsible for noxious stimuli, selective 
antagonists could be used for the treatment of acute and chronic pain (37). mGluRs also 
contribute to synaptic plasticity, induction of hippocampal LTP and enhancement cognitive 
function (70). mGluRIs dysfunction has been suggested to be involved in the pathogenesis of 
cognitive impairment and dementia in AD (3). Agonists of these receptors may have the 
potential to act as cognitive enhancing agents in patients with AD or other memory impairments.  
The mechanism of action of mGluR likely involves activation of the phosphatidylinositol 
3-kinase (PI3K) and MAPK signaling pathways, which in turn are likely lead to decreased ROS 
concentration and ultimately a decrease in oxidative stress and programmed cell death (54, 96). 
Additional evidence suggests that mGluRs regulate ROS production and oxidative stress albeit 
by different receptor groups depending upon the neurotoxic insult and neuronal type. Activation 
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of mGluRII by mGluR3 agonist APDC prevents the formation of ROS in the mitochondria and 
blocks caspase activation in DRG neurons in response to elevated glucose levels (222). More 
interestingly, Sagara & Schubert showed that mGluRI activation prevents oxidative stress-



















2.0  THESIS GOALS 
The goal of work presented in this thesis is to examine the mechanism of ERK1/2 activation 
under both pro- and anti-apoptotic conditions in a single cell type and investigate the relationship 
between these contrary actions of ERK1/2. This will be accomplished through the following two 
specific aims:  
 
Aim 1: To determine whether ERK1/2 activation is necessary and sufficient for 
glutamate induced cell toxicity.  
 
Aim1: Rationale: Previous reports from our lab have established that ERK1/2 
activation is biphasic with peak activation initially occurring within 30 min to 1 hr of 5mM 
glutamate treatment followed by a second peak of activation that initiates within 6 hr of 
glutamate exposure. U0126 treatment not only blocks ERK1/2 activation but also cell 
toxicity induced by glutamate. The second peak of ERK1/2 activation may be relevant for 
toxicity since delayed U0126 addition (2 hr following glutamate) is protective. However, the 
role of ERK1/2 in neuronal cell death is controversial. In contrast to the results found by our 
lab, studies from other groups have indicated that phosphorylation of ERK1/2 is essential to 
protect HT22 cells from death triggered by a variety of stimuli such as withdrawal of serum 
(200). Our previous studies were mainly based on a pharmacological strategy where U0126 
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was used to block ERK1/2 activation. More selective molecular tools, such as overexpression 
of a dominant negative mutant of the ERK1/2 activating kinase, MEK-1, would be useful to 
confirm the role of ERK1/2 in glutamate-induced oxidative toxicity.  The results from these 
studies are presented in Chapter 3. 
 
Aim 2: To examine the impact and mechanism of mGluR activation on oxidative 
toxicity and ERK1/2 activation.  
 
Aim2: Rationale. HT22 cells express metabotropic glutamate receptors (mGluRs) that 
are also activated in response to glutamate treatment. mGluR-mediated neuroprotection against a 
variety of insults is well established in the literature, and each of the subgroups has been 
documented to provide neuroprotection. For example, in HT22 cells and primary cortical 
neurons specific agonist and antagonist of mGluR type I (mGluRI) have anti- and proapoptotic 
roles, respectively (203). The mechanism of the neuroprotective action of mGluRI in these cells 
is not clear although it is likely to involve activation of the phosphatidylinositol 3-kinase (PI3K) 
and ERK1/2 signaling pathways. Thus, ERK1/2 activation may serve opposing roles in neuronal 
oxidative toxicity acting through mGluRs to promote survival while affecting distinct targets to 
induce cell death.  
The results of these studies shown in Chapter 3 provided insights into the link between 
mGluR activation, ERK1/2 activation and glutathione depletion in glutamate-induced oxidative 
toxicity in HT22 cells.  Specifically, I examined whether the early phase of ERK1/2 activation 
would provide a protective function against glutamate toxicity in HT22 cells through limiting 
glutathione depletion. In order to identify the mechanism of ERK1/2 effects on GSH 
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metabolism, I examined potential targets of ERK1/2 during the early and late phase of induction 
that may act to limit glutathione depletion. Glutathione synthesis, as discussed above is 
controlled by the first enzyme (rate limiting enzyme) in its synthetic pathway, GCL, which 
generates γ-L-glutamyl-L-cysteine (GC) from glutamate and cysteine. Therefore, I hypothesize 
that ERK1/2 may modulate GSH through regulating GCS, which is possibly dependent on the 


















3.0  DISTINCT MECHANISMS OF ERK1/2 ACTION AT EARLY VERSUS LATE 
PHASES OF OXIDATIVE STRESS 
3.1 SUMMARY 
Glutamate-induced oxidative toxicity is mediated by glutathione depletion in the HT22 mouse 
hippocampal cell line. Previous results with pharmacological agents implicated the extracellular 
signal-regulated kinases-1/2 (ERK1/2) in glutamate toxicity in HT22 cells and immature 
embryonic rat cortical neurons. In this report, we definitively establish a role for ERK1/2 in 
oxidative toxicity using dominant negative MEK1 expression in transiently transfected HT22 
cells to block glutamate-induced cell death. In contrast, chronic activation of ERK (i.e. brought 
about by transfection of constitutively active ERK2 chimera) is not sufficient to trigger HT22 
cell death demonstrating that ERK1/2 activation is not sufficient for toxicity. Activation of 
ERK1/2 in HT22 cells has a distinct kinetic profile with an initial peak occurring between 30 
minutes and 1 hour of glutamate treatment and a second peak typically emerging after 6 hours. 
We demonstrate here that the initial phase of ERK1/2 induction is due to activation of 
metabotropic glutamate receptor type I (mGluRI). ERK1/2 activation by mGluRI contributes to 
an HT22 cell adaptive response to oxidative stress as glutamate induced toxicity is enhanced 
upon pharmacological inhibition of mGluRI. The protective effect of ERK1/2 activation at early 
times after glutamate treatment is mediated by a restoration of glutathione (GSH) levels that are 
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reduced due to depletion of intracellular cysteine pools. Thus, ERK1/2 appears to play dual roles 
in HT22 cells acting as part of a cellular adaptive response during the initial phases of glutamate-
induced oxidative stress and contributing to toxicity during later stages of stress. 
3.2 INTRODUCTION 
Oxidative stress can contribute to neuronal toxicity and has been implicated in both acute injury 
and chronic neuropathological conditions (183, 217). Many in vitro models have been used to 
examine the mechanistic basis for neuronal cell death induced by oxidative stress. For example, 
oxidative toxicity can be induced by glutamate treatment in the HT22 mouse hippocampal cell 
line (42, 134, 226) and immature primary embryonic rat cortical neuron cultures (133, 134, 193). 
In these models, glutamate treatment leads to glutathione (GSH) depletion and subsequent 
accumulation of reactive oxygen species (ROS) (230). Many intracellular second messenger 
pathways are required for oxidative toxicity in HT22 cells including, arachidonic acid 
metabolites, cyclic GMP (cGMP) and calcium (230). In addition, signaling kinases, such as 
mitogen-activated protein kinases (MAPK), are activated upon glutamate-induced oxidative 
stress in HT22 cells and primary neurons and are likely to affect targets that either limit or 
promote oxidative toxicity.  
Extracellular signal-regulated kinases-1/2 (ERK1/2) has been implicated in glutamate-
induced neuronal oxidative toxicity based upon the neuroprotective effects of U0126, a specific 
inhibitor of the ERK1/2-activating kinase, MEK-1/2 (226). U0126 is also effective at reducing 
brain injury following focal ischemia in rodents suggesting that ERK1/2 may also promote 
neuronal cell death resulting from acute injury in vivo (169). However, the role of ERK1/2 in 
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neuronal cell death remains controversial (26, 34, 89). In a number of studies, ERK1/2 has been 
found to promote neuronal survival and reduce cell death induced by various insults (36, 75, 
221). Furthermore, even in HT22 cells, ERK1/2 may limit toxicity in response to specific insults 
such as serum withdrawal (200).  
Distinct kinetic profiles of ERK1/2 activation are observed in response to different 
extracellular signals and also can be associated with differential compartmentalization of active 
ERK1/2 within the cell. For example, in PC12 cells, prolonged, NGF-induced activation of 
ERK1/2 leads to its persistent accumulation within nuclei; however, rapid and transient EGF-
induced activation of ERK1/2 is unable to trigger its efficient nuclear translocation (36, 148). 
Interestingly, increasing evidence suggests that the kinetics and duration of ERK1/2 activation, 
as well as its subcellular localization, may direct ERK1/2 towards downstream targets that will 
either promote or limit neuronal survival (34, 36, 121).  
In HT22 cells and primary neurons, glutamate induces a biphasic activation of ERK1/2 
(226). Persistent activation of ERK1/2 in these cells is mediated primarily through the oxidative 
inhibition of select ERK phosphatases (132). However, the mechanisms responsible for the 
initial rapid activation of ERK1/2 by glutamate in HT22 cells and primary neurons are not 
known. Furthermore, the impact of the first wave of ERK1/2 activation on the response of HT22 
cells and primary neurons to oxidative stress has not been established.  
In this report, we show that rapid activation of ERK1/2 by glutamate in HT22 cells is 
driven by type I metabotropic glutamate receptors (mGluRIs). Furthermore, mGluRIs activation 
of ERK1/2 represents a cellular defense response that attempts to limit glutathione depletion 
resulting from glutamate induced cysteine depletion. This protective response mediated by 
ERK1/2 is however unable to overcome an overwhelming and chronic oxidative stress that 
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utilizes ERK1/2 in its final stages to promote neuronal cell death. Thus, ERK1/2 activation may 
serve opposing roles in neuronal oxidative toxicity acting initially through effects on glutathione 
metabolism to limit oxidative stress, but serving as a necessary signal to trigger cell death when 
cellular defense against oxidative stress is exhausted. 
3.3 MATERIALS AND METHODS 
Plasmids.  
The expression plasmids for LAERK2-MEK1 and ERK2-MEK1 were kind gifts from Dr. 
Melanie Cobb (198). pMCL-MEK1 Lys-97 Met (K97M), an HA-tagged dominant negative 
(DN) mutant of MEK1 was provided by Dr. Jane Cavanaugh (146). The mitochondrial-targeted 
enhanced yellow fluorescent protein (eYFP) expression plasmid was a gift from Dr. Ian 
Reynolds, while the expression plasmid for the ELK-1/GAL4 fusion protein, the luciferase 
reporter, and the constitutive renilla reporter plasmids were obtained from Strategene (La Jolla, 
CA).  
 
Cell culture.  
HT22 cells, a mouse hippocampal cell line, were maintained in Dulbecco’s minimal 
essential medium (DMEM) supplemented with 10% fetal calf serum (Atlanta Biologicals, 





Cell viability assay.  
HT22 cells grown in 24 well plates were incubated for 10 min with 1 μl (1:1000 dilution) 
of a 6.25 mg/ml solution of propidium iodide (PI) to visualize dead or dying PI-positive cells 
(133). Cells were observed under an inverted fluorescence microscope equipped with phase-
contrast optics (Nikon Eclipse TE200). Three random fields were counted for each condition in 
at least three separate cultures. For experiments that did not involve transfection, the fraction of 
PI-positive cells was scored relative to total cells per field visualized by phase contrast 
microscopy. In transfection experiments, the extent of PI positive staining was scored in eYFP-
positive transfected cells.  
 
Transfection and Western blotting.  
Cells were transfected with lipofectamine 2000 (Invitrogen, Carlsbad, CA) using 
conditions recommended by the supplier. During transfection, cells were maintained in serum- 
and antibiotic-free medium. Following 4 h of exposure to DNA-lipofectamine mixture, cells 
were refed with medium containing 10% FBS.  
On the following day, cells were washed, scraped and collected into ice-cold phosphate-
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 
7.4), pelleted at 2–3x 103 x g for 5 min, and disrupted in Lysis Buffer (50 mM Tris-Cl, pH 7.5, 2 
mM EDTA, 100 mM NaCl, 1% Nonidet P-40, 100 μM NaVO4, 100 μM NaF, 2 mM 
dithiothreitol) supplemented with 5 μl/ml of a protease inhibitor cocktail (Sigma Chemical 
Corporation, St. Louis, MO). The lysates were then centrifuged at 14,000 x g for 10 min at 4°C. 
Equivalent amounts of total protein, 30 μg, were separated by SDS-PAGE on 10% 
polyacrylamide gels and then transferred to polyvinylidene fluoride membranes (Millipore, 
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Bedford, MA). Membranes were blocked with 5% dry milk in PBS, 0.1% Tween 20. Membranes 
were then incubated with primary antibodies (anti- phospho- ERK and anti-total ERK both from 
Cell Signaling, Beverly, MA) overnight at 4°C with 3% dry milk, washed 3 x 10 min with PBS, 
0.1% v/v Tween 20, and then exposed to the appropriate horseradish-peroxidase conjugated 
secondary antibody for 1 h at room temperature. Membranes were again washed 3 x 10 min with 
PBS, 0.1% Tween 20, and immunoreactive bands were detected by enhanced 
chemiluminescence (ECL, Amersham Biosciences, Piscataway, NJ) using standard x-ray film 
(Kodak, Rochester, NY). Several different exposure times were used for each blot to ensure 
linearity of band intensities. Densitometry was performed using a Personal Densitometer SI 
(Molecular Dynamics, Amersham Biosciences) linked to the ImageQuant 5.2 software 
(Molecular Dynamics). 
 
Luciferase assay.  
Components of the Path Detect In Vivo Signal Transduction Pathway trans-Reporting 
System (Stratagene, La Jolla, CA) were used in order to monitor ELK-1-dependent transcription 
in HT22 cells (132). Cells were transfected with an expression plasmid coding for an ELK-
1/GAL4 fusion protein, a reporter plasmid containing the luciferase gene linked to a synthetic 
promoter containing 5 tandem GAL4 binding sites, a renilla expression plasmid, and various 
MEK1 expression plasmids (i.e. DN-MEK1, LA-MEK1ERK2). In this system, luciferase 
activity is a measure of the extent of ELK-1 activated transcription. Both luciferase activity and 
renilla activity were examined with the Dual-Glo Luciferase Assay System (Promega, Madison, 
WI) using a luminometer (Wallac Victor3, Perkin Elmer Biosciences, Boston, MA) according to 
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the manufacturer’s specifications. Results shown were from at least three separate experiments. 
All luciferase values were normalized to the internal control, renilla, within each sample.  
Glutathione concentration measurement.  
A glutathione assay kit from Cayman Chemical Company (Ann Arbor, MI) was used to 
measure glutathione concentrations. Cells from two 60 mm plates were collected and sonicated 
in 50 μl ice-cold lysis buffer (i.e. 50 mM MES buffer, pH6-7, containing 1 mM EDTA). After 
centrifuging at 10,000 x g for 15 min at 4°C, the supernatant was collected for deproteination 
with the exception of a small amount of cell lysate that was used to determine lysate protein 
concentration. Deproteination was necessary to avoid interference in the assay due to particulates 
and protein sulfhydryl groups. An MPA reagent (10% metaphosphoric acid in water; Sigma) and 
4 M TEAM reagent (triethanolamine from Sigma) were used to deproteinize lysates. An equal 
volume of ice-cold MPA was added to ice-cold supernatant and left on ice for 10 min. Samples 
were then centrifuged at 14,000 x g in a microfuge for 5 min at 4°C. 50 μl of TEAM reagent per 
ml of supernatant was added to supernatant. 50 µl of sample or standard provided in the kit was 
applied to each sample well. An Assay Cocktail mix was prepared with the following reagents: 
MES Buffer (11.25 ml), reconstituted Cofactor Mixture (0.45 ml), reconstituted Enzyme Mixture 
(2.1 ml), water (2.3 ml), and reconstituted DTNB (0.45 ml). 150 µl of the freshly prepared Assay 
Cocktail was added to each of the wells containing standards and samples. The plate was 
incubated in the dark on an orbital shaker at room temperature. Absorbance was measured at 405 
or 414 nm using a plate reader 25 min later. An end point method was used to calculate and 
determine the sample glutathione concentration according to the instructions provided by the 
supplier. All glutathione concentration values were normalized to the protein concentration 
within each sample. 
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Statistical analysis.  
Comparisons of multiple mean values were accomplished by analysis of variance 
(ANOVA) with Bonferroni's post-hoc tests for significance. Comparisons of two means were 
performed using a paired t-test. P values less than 0.05 were taken to be significant, and all data 
was analyzed using Graph Pad Prism version 3.0 for Windows (GraphPad Software, San Diego 
California USA). 
3.4 RESULTS 
3.4.1 ERK1/2 activation is necessary for glutamate-induced oxidative toxicity in 
HT22 cells 
ERK1/2 has been implicated in both neuronal cell survival and cell death although the basis for 
its disparate effects is not known. In fact, even in HT22 cells, opposing roles for ERK1/2 have 
been proposed (143, 200, 226). Since part of the discrepancy for ERK1/2’s role in neuronal cell 
survival may be due to secondary effects of pharmacological agents used to block ERK1/2 
activation, we used a molecular approach to definitively assess the role of ERK1/2 in HT22 cell 
response to oxidative stress.   
HT22 cells were therefore cotransfected with dominant negative MEK1 (DN-MEK1) and 
mitochondrial-targeted enhanced yellow fluorescent protein (mt-eYFP) expression plasmids. 
Since the cotransfected plasmids enter cells with equal probability, eYFP positive cells were 
likely to contain DN-MEK1 DNA. DN-MEK1 contains a point mutation at position 97 (i.e. 
lysine to methionine) that inactivates its kinase activity (146). As a result, the DN-MEK1 
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interferes with activation of wild type MEK1. Cell death was measured in transfected cells 7 h 
after 5 mM glutamate treatment using a PI staining assay (133). As shown in Figure 5A, DN-
MEK1 overexpression blocked glutamate induced oxidative toxicity in HT22 cells. These data 
confirm our previous results with a pharmacological inhibitor of MEK1 (i.e. U0126) and 
demonstrate that ERK1/2 activation is necessary for glutamate toxicity.  
To confirm the inhibitory effect of DN-MEK1 on ERK1/2 activation, we used a sensitive 
assay to detect functional ERK1/2 in nuclei. Specifically, HT22 cells were transfected with the 
DN-MEK1 expression plasmid along with an expression vector for an ELK-1-GAL4 fusion 
protein and a luciferase reporter gene under the control of a promoter containing 5 tandem GAL4 
DNA binding sites i.e. GAL4 UAS-luciferase (UAS: upstream activator sequences). Given that 
ELK-1 is an established nuclear target of ERK1/2, enhanced transactivation activity resulting 
from its phosphorylation by nuclear localized ERK1/2 is easily monitored through the activity of 
the luciferase reporter (132).  
As shown in Figure 5B, 10 μM U0126 treatment decreased luciferase activity from 
GAL4UAS-reporter significantly in both untreated and glutamate treatment HT22 cells. 
Luciferase activity from the Gal4UAS-luciferase reporter was induced nearly two-fold following 
a 7 h treatment with 5 mM glutamate (Fig 5B) consistent with previous results of ERK1/2 
activation using this assay (132). The expression of DN-MEK1 significantly reduced luciferase 
activity from the GAL4UAS-reporter in glutamate treated cells (Fig 5C). The reduced 
effectiveness of DN-MEK1 to block ELK-1 activated transcription relative to U0126 treatment 
most likely results from variable expression of the DN-MEK1 within individual transfected cells. 
Nonetheless, these results confirm the expected inhibition of ERK1/2 activity in the nucleus of 
HT22 cells upon overexpression of DN-MEK1.  
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3.4.2 Prolonged ERK activation is not sufficient to induce toxicity in HT22 cells 
In order to assess whether chronic activation of ERK was sufficient to induce toxicity in HT22 
cells, we used constitutively active (CA) ERK2 chimeric proteins. MEK1ERK2 is a fusion 
protein with constitutive ERK2 activity that localizes in the cytoplasm (198). In the CA ERK2 
fusion LAMEK1ERK2, four leucines in MEK1 that are crucial for its nuclear export have been 
mutated to alanines (67). As a result, the LAMEK1ERK2 fusion protein is localized in the 
nucleus (198). Furthermore, by virtue of its retention within nucleus, LAMEK1ERK2 exhibits a 
5-10 fold higher ERK2 activity than MEK1ERK2 (198). To verify the activation of ERK 
signaling by LAMEK1ERK2, the Path Detect in Vivo Signal Transduction Pathway trans-
Reporting System was used to access ELK-1-dependent gene expression. 
MEK1ERK2/LAMEK1ERK2 expression plasmids along with an expression vector for an ELK-
1/GAL4 fusion protein and the GAL4UAS-luciferase reporter gene were transfected into HT22 
cells. Cell lysates were collected and luciferase activity was measured 18 h after transfection. As 
shown in Figure 6A, LAMEK1ERK2 overexpression can induce robust ERK1/2 activation 
compared to that of MEK1ERK2. The enhanced activation of the GAL4UAS luciferase reporter 
in LAMEK1ERK2 transfected cells likely results from its more efficient localization within 
nuclei.  
We then accessed the effects of LAMEK1ERK2 overexpression on HT22 cell viability 
using the PI staining method. As shown in Figure 6B, both LAMEK1ERK2 and MEK1ERK2 
transfected cells showed no enhanced toxicity as compared to empty vector transfected HT22 
cells. Robust ERK activation upon overexpression of LAMEK1ERK2 chimera also did not 
unleash toxicity in HT22 cells exposed to a low dose of glutamate (1.5 mM). As will be shown 
below, 1.5 mM glutamate can trigger cell death under conditions of altered mGluRIs activity. 
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Thus, although necessary, prolonged ERK activation is not sufficient to induce toxicity in HT22 
cells nor does it predispose cells to toxicity under conditions of minimal glutamate exposure. 
3.4.3 Metabotropic glutamate receptors group I (mGluRIs) are involved in 
glutamate-induced oxidative toxicity 
HT22 cells express both type 1 and type 5 metabotropic glutamate receptors (mGluR1 and 
mGluR5) (203). These receptors are likely to be activated during glutamate exposure that 
triggers oxidative stress. Since mGluRIs have been suggested to play a protective role in 
glutamate toxicity (203), we sought to examine their role in promoting or attenuating ERK1/2 
dependent toxicity in HT22 cells. HT22 cells were therefore pretreated with a mGluRI antagonist 
(R,S)-1-aminoindan-1,5-dicarboxylic acid (AIDA) or mGluRI agonist (R,S)-3,5-
dihydroxyphenylglycine (DHPG) at 500 or 1000 μM respectively. Glutamate was added 30 min 
later at 5 mM (maximally toxic dose) or at 1.5 mM, a dose that exhibits minimal cytotoxic 
effects. Seven hours after 5 mM glutamate and 22 h after 1.5 mM glutamate treatment, cell 
viability was measured by PI staining. 1.5 mM glutamate treatment of HT22 cells for 22 h only 
results in a 17% reduction in cell viability as assessed by PI staining (Fig 7A). However, a 30 
min pretreatment with AIDA potentiated toxicity in the presence of 1.5 mM glutamate resulting 
in 66% cell death after 22 h (Fig 7A). In contrast, a 30 min pretreatment of HT22 cells with 
DHPG significantly reduced the minimal toxicity induced by 1.5 mM glutamate treatment to 5% 
(Fig 7A). By blocking ERK1/2, the toxicity observed in HT22 cells treated with glutamate and 
AIDA or DHPG was reduced. In HT22 cells treated with 5 mM glutamate, AIDA and DHPG 
have similar effects as those observed in 1.5 mM glutamate treated cell (Fig 7B). These results 
confirm that mGluRIs play a role in limiting oxidative toxicity induced by glutamate treatment 
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(203) and establish that limiting mGluRIs activation promotes ERK1/2 dependent toxicity at sub-
threshold levels of glutamate.  
3.4.4 Effects of mGluRIs activation on the ERK1/2 activation in glutamate-
induced oxidative toxicity 
Given the protective effects of mGluRIs activation on ERK1/2 dependent oxidative toxicity in 
HT22 cells, we set out to investigate whether mGluRIs impacts ERK1/2 activation. Western 
blots were therefore performed with lysates prepared from HT22 cells treated with 1.5 mM 
glutamate and AIDA or DHPG and probed to detect phosphorylated ERK1/2. In order to assess 
the kinetics of ERK1/2 activation under the various conditions, protein samples were then 
collected at different time points (i.e. 30 min, 1 h, 6 h, 10 h and 22 h) following glutamate 
addition. In all cases, the extent of ERK1/2 activation was measured relative to total ERK1/2 
quantified from stripped blots (e.g. see Fig 9). 
As shown in Figure 8A, treatment of HT22 cells with 1.5 mM glutamate alone induced a 
3 fold activation of ERK1/2 that peaked within 30 min. ERK1/2 activation did not persist and 
eventually was reduced to levels approximately 40% below baseline following 10 h of treatment 
with 1.5 mM glutamate (Fig. 8A). Continued exposure to 1.5 mM glutamate alone (i.e. 22 h 
total) generated a second peak of ERK1/2 activation (Figs. 8A and 9B). 
A role for mGluRIs in rapid transient activation of ERK1/2 by 1.5 mM glutamate was 
supported by the observed prevention of this activation by a 30 min pretreatment with AIDA 
(Fig 8B). Specifically, the early phase of ERK1/2 activation (i.e. within 30 min of glutamate 
treatment) was reduced 34% by AIDA (Fig 9A). The addition of DHPG along with 1.5 mM 
glutamate did not lead to a significant effect on the initial phase of ERK1/2 activation (Fig 9A). 
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Base line levels of activated ERK1/2 during the nadir between early and late phases of activation 
were often lower than that observed in unstimulated cells. Therefore, we compared the extent of 
ERK1/2 activation at 22 h relative to 10 h of glutamate treatment to more clearly illustrate the 
late phase of activation (Fig 9B). 
Using this approach, we observed that AIDA enhanced the second phase of ERK/2 
activation nearly 4 fold (Fig 9B). However, continuous exposure of HT22 cells to 1.5 mM 
glutamate and DHPG did not generate a second peak of ERK1/2 activation (Fig 9B). These 
results identify a dual role for mGluRIs in regulating ERK1/2 activation. Activation of mGluRIs 
by glutamate triggers activation of ERK1/2 that may function to limit toxicity. However, in the 
absence of mGluRIs activation, a delayed activation of ERK1/2 is enhanced that functions to 
promote cell death.  
3.4.5 The role of ERK1/2 in glutathione depletion 
Glutamate induced oxidative toxicity is triggered by glutathione depletion (230). A role 
for ERK1/2 in this component of glutamate toxicity has not been established. We therefore 
measured intracellular glutathione concentrations at various times after glutamate treatment in 
the presence or absence of U0126. Consistent with previous studies, a 5 mM glutamate treatment 
induced prolonged glutathione depletion in HT22 cells (Fig 10A). GSH levels dropped to 84% in 
2 h and 33% in 6-8 h relative to basal line levels. Although U0126 protects HT22 cells from 
glutamate toxicity, it does not trigger the restoration of GSH levels in glutamate treated HT22 
cells (Fig 10B). In this experiment, U0126 was added coincident with glutamate and therefore 
blocked both early and late phases of ERK1/2 activation. However, when U0126 was added 2 h 
following 5 mM glutamate treatment to allow for the early but not late phase of ERK1/2 
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activation, GSH levels returned to about 82% of basal line levels within 22 h (Fig 10C). This 
delay in U0126 treatment protects HT22 cells from glutamate toxicity (226). Thus, ERK1/2 
activation via mGluRIs signaling within the first few hours of glutamate treatment is required for 
HT22 cells to restore GSH levels that were reduced due to cysteine depletion. 
As illustrated above, a suboptimal dose (i.e. 1.5 mM) of glutamate generates minimal 
toxicity in HT22 cells that is only apparent following prolonged exposure (22 h). Therefore, we 
investigated the kinetics of GSH depletion in response to a low dose of glutamate. Under these 
conditions, ERK1/2 activation is observed only at early times after glutamate addition. 1.5 mM 
glutamate induced an early depletion of GSH in 4-8 h to about 27% of basal line levels, which is 
comparable to the extent of GSH depletion in 5 mM glutamate treated cells. However, a rebound 
in GSH levels occurred between 16-22 h which restores GSH to basal line levels (Fig 10D). 
Interestingly, inhibition of mGluRIs activation by a 30 min pretreatment with AIDA abolished 
the rebound in GSH levels that occurs in response to a 1.5 mM glutamate treatment. GSH levels 
remained low (i.e. 18-46% of basal line levels) from 4-22 h (Fig 10E). Under these conditions, 
only the late phase of ERK1/2 activation is observed. Thus, in the absence of mGluRIs 
activation, a compensatory mechanism that acts to restore GSH levels is not operating and cell 
death can result in HT22 cells from even a minimal exposure to glutamate.  
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 Figure 5. DN-MEK1 reduces ERK1/2 activition and blocks glutamate-induced toxicity in HT22 cells. 
(A) HT22 cells were cotransfected with either an empty plasmid vector or DN-MEK1 
and mt-eYFP. The following day, cell death was induced by a 7 h treatment with 5 mM 
glutamate. Cell death in transfected cells was measured using a PI staining assay and was 
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expressed as the percentage of PI and mt-eYFP double positive cells relative to the total mt-
eYFP positive cells. The percentage of cell death was decreased from 48% to 5% by expression 
of DN-MEK1. Data shown are from 3 separate experiments (** P<0.01). 
(B) HT22 cells were transfected with an empty plasmid vector and then treated with 
either DMSO, 10 μM U0126, 5 mM glutamate or glutamate plus U0126. Luciferase activity was 
measured from a cotransfected ELK-1 reporter plasmid. Luciferase activity from the Gal4UAS-
luciferase reporter was induced nearly two-fold upon a 7 h 5 mM glutamate treatment. However, 
U0126 inhibited luciferase activity in both DMSO and glutamate treated groups (C) DN-MEK1 
expression decreased ELK-1 driven luciferase activity in cells treated for 7 h with 5 mM 
glutamate. (*P<0.05, **P<0.01). 
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 Figure 6. Chronic activation of ERK1/2 is not sufficient to induce HT22 cell death. 
 (A) A constitutively active (CA) LAMEK1-ERK2 fusion plasmid was transfected into 
HT22 cells and luciferase activity measured from an ELK-1driven luciferase reporter plasmid. 
Expression of LAMEK1ERK2 plasmid induced a robust increase in luciferase activity compared 
to transfections with a MEK1ERK2 plasmid (**P<0.01). 
(B) HT22 cells were transfected with LAMEK1ERK2 (LA), MEK1ERK2 fusion plasmid 
or empty vector PSG5 (PSG5). Cell toxicity was detected using the PI staining assay in the 
presence or absence of a 22 h 1.5 mM glutamate treatment (Glu). Activation of ERK1/2 in LA 
transfected cells did not trigger cell death (*P<0.05).  
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 Figure 7. Effects of mGluRI activation or inactivation on glutamate toxicity in HT22 cells. 
The percentage of cell death was measured using a PI staining assay as described above. 
The mGluRI antagonist AIDA enhanced glutamate (Glu) toxicity while the mGluRI agonist 
DHPG decreased glutamate toxicity at both 1.5 mM (A) and 5 mM glutamate (B). In both 
groups, U0126 prevented cell death (*P<0.05, ***P<0.001).  
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Figure 8. Kinetics of ERK1/2 activation following glutamate treatment. 
Western blot analysis in A, B and C show p-ERK1/2 and total ERK1/2 levels in lysates 
prepared from HT22 cells treated for various lengths of time with 1.5 mM glutamate. (A) 
Treatment of HT22 cells with 1.5 mM glutamate alone induced a transient 3 fold activation of 
ERK1/2 (n=3) within 30-60 min. ERK1/2 activation did not persist and returned to basal line 
levels within 10 h. Upon continuous exposure to 1.5 mM glutamate, activated ERK1/2 levels 
gradually increased above its nadir attained between 4-6 h following glutamate addition. (B) 
Pretreatment of HT22 cells with AIDA blocked the transient activation of ERK1/2 while 




 Figure 9. Quantitative analysis of ERK1/2 activation in glutamate treated HT22 cells. 
Autoradiograms from Western blots shown in Figure 8 and replicates were subjected to 
densitometric analysis and relative pERK1/2 levels (normalized to total ERK1/2) were quantified 
using NIH Image (n>=3). As shown in (A), AIDA inhibited by 4 fold the activation of ERK1/2 
that occurs within 30 min of 1.5 mM glutamate treatment (*P<0.05). DHPG did not significantly 
affect ERK1/2 activation within 30 min of glutamate treatment. (B) The second phase of ERK1/2 
activation is illustrated by comparisons of ERK1/2 phosphorylation at 22 versus 10 h of 1.5 mM 
glutamate treatment. An AIDA pretreatment enhanced this late phase of ERK1/2 activation 
approximately 3 fold while DHPG inhibited the late phase of ERK1/2 activation 5 fold 
(*P<0.05).  
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 Figure 10. Effects of ERK1/2 on glutathione depletion. 
(A) HT22 cells were treated with 5 mM glutamate and GSH levels measured at 2, 4, 6 
and 8 h afterwards. A significant reduction of GSH levels to 30% of basal line levels was 
detected by 6-8 h. (B) HT22 cells were treated with 5 mM glutamate and 10 μM U0126 
simultaneously and GSH levels examined 4, 8, 16 and 22 h afterwards. U0126 did not affect 
GSH depletion during the time course although it blocks glutamate toxicity. (C) HT22 cells were 
exposed to 10 μM U0126 2 h after the initiation of a 5 mM glutamate treatment and GSH levels 
examined 4, 8, 16 and 22 h after glutamate addition. GSH levels decreased to 25% and 11% after 
4 and 8 h respectively. A rebound of GSH levels to 82% was observed within 22 h of glutamate 
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treatment. (D) HT22 cells were treated with 1.5 mM glutamate and GSH levels assayed at 4, 8, 
16 and 22 h afterwards. 1.5 mM glutamate induced a significant decrease of GSH in 4-8 h which 
rebounded to basal line GSH levels within 16-22 h. (E) HT22 cells were pretreated with AIDA 
for 30 min then exposed to 1.5 mM glutamate. GSH levels were assayed at 4, 8, 16 and 22 h 
afterwards. AIDA treatment induced a prolonged and significant GSH depletion.  
Data shown above are representative of 4 separate experiments. The GSH reading was 
normalized to protein concentration. HT22 cells’ GSH level was set as 100% (*P<0.05, 

















3.5.1 ERK1/2 and Neuronal Cell Death 
It is now well recognized that ERK1/2 plays disparate roles in neurons, acting in some cases to 
promote cell survival (46, 221) while also participating in neuronal cell death and the 
pathogenesis of neurodegeneration (34). While a mechanistic basis for diverse effects of ERK1/2 
in neurons is beginning to emerge, it is often difficult to make meaningful comparisons of results 
obtained in different cell lines or neuronal cell types. In this study, we have uncovered both 
prosurvival and cell-death promoting activity of ERK1/2 in one neuronal cell line exposed to a 
single toxic stimulus. We (226) and others (73) had previously shown that ERK1/2 is required 
for glutamate-induced oxidative toxicity relying principally on results obtained with 
pharmacological inhibitors of ERK1/2 activation such as the MEK1 inhibitor U0126. In the 
present study, we provide more definite support for this conclusion by showing a protective 
effect of DN-MEK1 on glutamate-induced oxidative toxicity in HT22 cells. Interestingly, we 
also showed that chronic ERK1/2 activation itself is not sufficient to induce cellular toxicity. 
Thus, ERK1/2 must cooperate with other pathways or cellular components affected by oxidative 
stress to contribute to toxicity. 
Our initial studies of the kinetics of ERK1/2 activation in response to glutamate treatment 
revealed a biphasic pattern with an early peak of activation occurring within 30-60 minutes and a 
second peak emerging within approximately 6-8 hours (226). While recent results from our 
laboratory established a role for oxidative inhibition of ERK1/2 phosphatases in the second peak 
of ERK1/2 activation in glutamate-treated HT22 cells and primary cortical neurons (133), the 
signaling pathway that triggers the initial phase of ERK1/2 activation in these models remained 
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undefined. In this report, we show that the initial phase of ERK1/2 activation is due to the 
activation of mGluRI. The transient nature of this rapid activation of ERK1/2 is likely due to 
desensitization of mGluRI which occurs upon continuous exposure of HT22 cells to glutamate 
(203). Importantly, our results demonstrate that ERK1/2 can indeed function as it does in many 
other neuronal and non-neuronal cells, as a pro-survival kinase. Specifically, in early phases of 
glutamate-induced oxidative stress, ERK1/2 is a component of a cellular defense pathway that 
seeks to overcome oxidative stress by restoring depleted glutathione levels. However, as 
oxidative stress continues to develop, this cellular defense pathway is overwhelmed, perhaps due 
in part to desensitization of mGluRI, and ERK1/2 becomes a necessary player as oxidatively-
stressed cells enter the final stages of a unique cell death pathway (230). If the initial phase of 
ERK1/2 activation is blocked (i.e. by a mGluRI antagonist), HT22 cells become hypersensitive 
to a subthreshold dose of glutamate. The toxicity that results in HT22 cells from low doses of 
glutamate in the absence of mGluRI action remains ERK1/2 dependent. 
3.5.2 Mechanism of ERK1/2 activation by mGluRIs 
mGluRs are G protein-coupled receptors (GPCR) with seven transmembrane domains. These 
receptors have been implicated in a variety of physiological functions, including 
neurotransmission, long-term potentiation, and reciprocal interactions with the ionotropic 
glutamate receptors (37). mGluR-mediated neuroprotection against a variety of insults is well 
established, and each of the subgroups has been shown to provide neuroprotection in various 
contexts. Furthermore, activation of mGluRs has been shown to be protective against a variety of 
neurotoxic insults in vivo including spinal cord injury, ischemia, epilepsy, multiple sclerosis, 
amyotrophic lateral sclerosis and more recently oxidative stress and diabetes (222).  
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HT22 cells and primary embryonic rat cortical neurons lack ionotropic glutamate 
receptors (144) and do not express mGluRII (203). Therefore, HT22 cells serve a good model to 
illustrate the role of mGluRI in neuronal cell death. In fact, specific agonists and antagonists of 
mGluRIs have been shown to have anti- and proapoptotic roles, respectively in HT22 cells and 
primary cortical neurons (203). Our results not only establish ERK1/2 as a mediator of mGluRI 
effect on oxidative toxicity but identify the downstream target of ERK1/2 (i.e. glutathione 
metabolism, see below) that is responsible for its initial neuroprotective effects.  
The pro-survival effects of mGluR have previously been shown to be due to activation of 
the phosphatidylinositol 3-kinase (PI3K) and MAPK signaling pathways, which in turn may lead 
to decreased ROS accumulation (54, 96). Additional evidence suggests that mGluRs regulate 
ROS production and oxidative stress albeit by distinct subtypes (e.g. group I, II and III) 
depending upon the neurotoxic insult and neuronal type. For example, activation of mGluRII 
prevents ROS generation in the mitochondria of dorsal root ganglia neurons in response to 
elevated glucose levels (222). The mechanism of the neuroprotective action of mGluRI in these 
cells was not clear although it was suggested to involve activation of PI3K and ERK1/2 signaling 
pathways (54, 96). Our results confirm the neuroprotective effects of mGluRI in HT22 cells and 
establish a role for ERK1/2 activation in mGluRI action to limit toxicity. Unfortunately, this 
protective response of HT22 cells driven by active ERK1/2 is not sufficient to overcome the 
overwhelming oxidative stress that ensues following prolonged exposure to a high concentration 
of glutamate.  
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3.5.3 ERK1/2 activation and glutathione depletion  
Glutathione is the predominant non-protein thiol antioxidant in mammalian and plant cells (64). 
Glutamate, cysteine and glycine are the three precursors of GSH, which plays an important role 
in many cellular processes such as metabolism of xenobiotic (110) and endogenous oxidants, cell 
proliferation (52), and regulation of gene transcription (10). Among those, the most well-known 
function of GSH is antioxidant defense by acting as a coenzyme in glutathione peroxidase or 
GST-catalyzed reactions (49, 63, 253). GSH depletion has been implicated in the pathogenesis of 
many neurological diseases such as Parkinson’s disease (102). Although some cells can take up 
GSH directly from their surroundings, adequate GSH levels are maintained by de novo synthesis. 
GSH concentrations in cells are determined by the balance of its synthesis and consumption. As 
discussed and evaluated by Hansen (2004), GSH synthesis is controlled by the first enzyme (rate 
limiting enzyme) in the synthetic pathway, glutamate-cysteine ligase (GCL), which converts 
glutamate to cysteine (83). Some environmental factors can alter intracellular GSH levels by 
influencing this reaction (52). For example, H2O2 (190) and some reactive species generated 
during exposure to toxins could upregulate GSH production (215). Unfortunately, this increase is 
limited and short-lived (49). 
GSH depletion and elevations in ROS levels do not represent the terminal, irreversible 
phase of cell death in oxidatively stressed HT22 cells. The protective effects of U0126 are not 
associated with a restoration of GSH levels (this report) or reduction in elevated ROS (226). 
Therefore, active ERK1/2 is more proximal to the irreversible step in HT22 cell oxidative 
toxicity and is downstream of ROS activation. Although there is not a link between GSH 
metabolism and the death promoting action of the late phase of ERK1/2 activation, the initial 
pro-survival effects of active ERK1/2 (i.e. driven by mGluRI activation) appear to be due to its 
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impact on GSH metabolism. Specifically, in HT22 cells that are triggered to activate ERK1/2 
only at early times after glutamate addition (i.e. delayed U0126 addition), a rebound occurs that 
restores GSH to basal line levels. Without the initial activation of ERK1/2, this restoration of 
GSH levels in glutamate treated HT22 cells does not occur.    
Previous studies in HNE treated L2 cells (rat lung epithelial) have shown that inhibition 
of ERK1/2 by PD98059 blocked GCLc (catalytic subunit of GCL) mRNA but not GCLm 
(modulator subunit of GCL) mRNA (49). Furthermore, ERK1/2 was found to upregulate 
GCLc/GCLm mRNA through two possible pathways. One is through the increase in AP-1 DNA 
binding and the other through an increase in binding of the Nrf2 transcription factor to ARE 
binding sites (97). Future studies will reveal whether any of these mechanisms apply to the effect 
of ERK1/2 on GSH metabolism in HT22 cells.     
3.6 CONCLUSIONS 
In summary, the dual roles of ERK1/2 as a prosurvival and death promoting kinase can be 
observed within a single neuronal cell type (i.e. HT22 cells) exposed to a single toxin (i.e. 
glutamate). Specifically, at early stages of glutathione depletion-induced oxidative stress, 
ERK1/2 influences GSH metabolism and facilitates the recovery of GSH levels while at later 
stages, ERK1/2 becomes a necessary component of oxidative toxicity. Thus, any therapeutic 
intervention directed at the ERK1/2 pathway must take into account the divergent effects of this 
signaling pathway particularly within cells and tissues where oxidative stress is a contributing 
factor in cell death.  
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4.0  POSSIBLE MECHANISM OF ERK1/2 REGULATION TO GLUTATHIONE 
THROUGH GLUTAMATE-CYSTEINE LIGASE (GCL) FOLLOWING GLUTAMATE-
INDUCED OXIDATIVE TOXICITY IN HT22 CELLS 
4.1  INTRODUCTION   
ERK1/2 activation exerts different effects on GSH depletion during the early and late phases of 
glutamate treatment but the mechanism responsible for ERK1/2 effects on GSH metabolism are 
unknown. Distinct targets of ERK1/2 differentially affected during the early and late phases of 
induction that may act to limit glutathione depletion were examined.  
GSH biosynthesis is regulated by the activity of the biosynthetic enzymes and the 
availability of cysteine (97). Glutathione synthesis, as discussed in the Introduction, is controlled 
by the first enzyme (rate limiting enzyme) in the synthetic pathway, glutamate-cysteine ligase 
(GCL), which creates γ-L-glutamyl-L-cysteine (GC). The second enzyme required for de novo 
synthesis of glutathione is glutathione synthase (GS), formerly called glutathione synthetase. The 
GCL holoenzyme is a heterodimer of ~104 kDa. It can be separated under non-denaturing 
conditions to yield two subunits, a catalytic (GCLC; 73 kDa) and a modulatory (GCLM; 31 kDa) 
subunit (66). The GCLM has a modulatory function affecting the affinity of the GCLC for 
glutamate and GSH (94). The GCLM protein contributes to the decreased feedback inhibition of 
 67 
GSH to GCLC in transgenic mice expressing the HIV transactivator Tat in liver (33) and aged 
rats brain tissue (137).  
As GCL activity is feedback-inhibited by GSH, rapid depletion of intracellular GSH by 
conjugation reactions or other reasons can increase GCL activity. Therefore rapid GSH increases 
are thought to occur via increased activity of existing GCL as an adaptive response (32). 
However, as the rate-limiting enzyme during GSH synthesis, increased GCL gene expression has 
also been reported to act to maintain intracellular glutathione homeostasis during oxidative stress 
(52, 220).  
A large number of conditions have been shown to regulate intracellular GSH 
concentrations through increased GCL activity. These conditions include exposure to quinones 
(140), heavy metal mercury (252), ionizing radiation (164), ROS such as H2O2 (177, 190), nitric 
oxide (161) or ROS producing compounds (248). It has been observed that the effect of stimuli 
on GCL and GSH levels may be agonist, model (in vivo vs in vitro), species, and even cell type 
specific.  
Recent studies have shown that nuclear factor erythroid2-related factor 2 (Nrf2) governs 
basal and inducible GCL subunits expression by means of an antioxidant response element 
(ARE) contained within the GCL promoter (228). Also, inhibition of ERK1/2 or p38 kinases by 
PD98059 or SB202190, respectively, results in a 50% reduction in GCL gene induction, while 
simultaneous inhibition completely eliminates induction in HepG2 cells. Induction of GCL 
expression is associated with an increase in the binding of transcription factors such as Nrf2 and 
AP1 to the GCL ARE (268).  
Therefore, I hypothesize that ERK1/2 may modulate GSH through regulating GCL gene 
transcription. I detected changes in GCL protein and mRNA levels at different times after 
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glutamate treatment, which is consistent with effects of ERK1/2 on GSH levels. The 
combination of glutamate with AIDA pretreatment was used to examine whether the change of 
GCLC and GCLM expression is due to glutamate activation of mGluRIs. 
 
4.2  MATERIAL AND METHODS 
Cell culture  
HT22 cells, a mouse hippocampal cell line, were maintained in Dulbecco’s minimal 
essential medium (DMEM) supplemented with 10% fetal calf serum (Atlanta Biologicals, 
Norcross, GA), 100 units of penicillin, and 100 μg/ml streptomycin at 37°C and 5% CO2. 
 
Cell viability assay  
HT22 cells grown in 24 well plates were incubated for 10 min with 1 μl (1:1000 dilution) 
of a 6.25 mg/ml solution of propidium iodide (PI) to visualize dead or dying PI-positive cells 
(133). Cells were observed under an inverted fluorescence microscope equipped with phase-
contrast optics (Nikon Eclipse TE200). Three random fields were counted for each condition in 
at least three separate cultures. The fraction of PI-positive cells was scored relative to total cells 
per field visualized by phase contrast microscopy.  
 
Chemicals  
2(3)-tert-butyl-4-hydroxyanisole (BHA) (Cat# B1253, from Sigma) was dissolved in 
absolute ethanol. The stock of 200mM BHA is saved in -20oC.   
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mGluRI antagonist (R,S)-1-aminoindan-1,5-dicarboxylic acid (AIDA) (Cat# 0904, from 
Tocris  Bioscience, Ellisville, Missouri) was dissolved in 1.1eq. NaOH. The stock of 100 mM is 
saved at -80 oC. mGluRI agonist (R,S)-3,5-Dihydroxyphenylglycine (DHPG) (Cat# 0342, from 
Tocris  Bioscience, Ellisville, Missouri) was dissolved in 1 eq. NaOH. The stock of 100 mM is 
saved at -80 oC. 
L-glutamic acid (Cat# G-5889, from Sigma) was dissolved in water to 1M, filtered then 
stocked in -20 oC. MEK1 inhibitor, 1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) 
butadiene (U0126) (Cat# 662005, from Calbiochem, San Diego, California) was dissolved in 
DMSO. The stock of 10 mM is saved at -20 oC.  
 
RT-PCR (reverse transcription-polymerase chain reaction)  
Total RNA was extracted from HT22 cells using the RNeasy Mini kit (Qiagen, Valencia, 
CA) according to the instructions provided by manufacturer. To reverse transcript, 1 µg of RNA 
was incubated with 100 µl of reaction mix containing 25 mM MgCl2, 25 mM deoxynucleotide 
triphosphates (PerkinElmer), 10x PCR II Buffer (Life Technologies), 40 U/µl RNAsin RNase 
inhibitor (Promega), 45 µM random hexamers (Integrated DNA Technologies, Coralville, IA), 
200 U/µl Superscript reverse transcriptase (Life Technologies), and nuclease-free water 
(Ambion). Control experiments were performed without reverse transcriptase to control for the 
contamination of DNA. The samples were incubated at 25oC for 10 min, at 48oC for 30 min, and 
at 95oC for 5 min followed by 4oC for 5 min to inactivate the reverse transcriptase. 
For amplification, a PCR containing a cDNA aliquot along with AmpliTaq Gold DNA 
polymerase in a volume of 25 µl was used according to the manufacturer’s instructions (Applied 
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Biosystems, Foster City, CA). The sequences of the primers and probes are as follows (all 
sequences 5' to 3'): Gclc sense primer, ATGTGGACACCCGATGCAGTATT; Gclc antisense 
primer, TGTCTTGCTTGTAGTCAGGATGGTTT; Gclm sense primer, 
GCCACCAGATTTGACTGCCTTT; Gclm antisense primer, 
CAGGGATGCTTTCTTGAAGAGCTT; GAPDH: sense primer, 5'-
CATCACCATCTTCCAGGAGCGAGA-3'; and antisense primer, 5'-
GTCTTCTGGGTGGCAGTGATGG-3'. Expression levels were derived from comparison with 
serial dilutions of a known reference standard and values are normalized to GAPDH. 
Thermocycling conditions involved an initial denaturation step at 94oC for 12 min followed by 23 
cycles at 94oC for 30 sec and 56oC for 30 sec and 72oC for 30 sec. Specific PCR amplification 
products were separated on a 12% PAGE and detected by Ethidium Bromide (EtBr) staining. 
Experiments were performed with at least triplicates for each data point.   
 
Western blotting 
Cells were collected and prepared as described in Chapter 2. The protein samples were 
separated by SDS-PAGE on 10-12% polyacrylamide gels and then transferred to polyvinylidene 
fluoride membranes. After blocking with 5% dry milk in PBS, 0.1% Tween 20, membranes were 
incubated with primary antibodies/antisera (anti-GCLC and anti-GCLM both provided by Dr. 
Terrance Kavanagh; anti-Nrf2 (Sc-722) from Santa Cruz biotechnology Inc, California; anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, CSA-335) from Stressgen, Victoria, 
British Columbia, Canada) overnight at 4°C with 3% dry milk, washed 3 x 10 min with PBS, 
0.1% v/v Tween 20, and then exposed to the appropriate horseradish-peroxidase conjugated 
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secondary antibody for 1 h at room temperature. See the details of the following development 
and analysis steps in Chapter 3. 
  
 
Statistical analysis  
Comparisons of multiple mean values were accomplished by analysis of variance 
(ANOVA) with Bonferroni's post-hoc tests for significance. Comparisons of two means were 
performed using a paired t-test. P values less than 0.05 were taken to be significant, and all data 




4.3.1 Alterations in GCL mRNA levels following glutamate treatment in HT22 
cells 
The mRNA levels of GCLC and GCLM were examined in HT22 cells treated with 5mM 
glutamate and 1.5mM glutamate in the presence or absence of a pretreatment with the mGluRI 
antagonist AIDA. RNA samples were extracted from HT22 cells and then RT-PCR experiments 
were performed with corresponding primers. All of the RT-PCR results were repeated more than 
3 times and normalized to mRNA levels of the housekeeping GAPDH gene.  
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The results showed that 5mM glutamate induced a slight increase in both GCLC and 
GCLM mRNA levels that appeared to peak around 2 hours (Fig 11A). The strongest induction 
was obtained after a 2 hr glutamate treatment as shown in Fig 11, with a 1.7 and 2 fold induction 
in GCLC (Fig 11B) and GCLM (Fig 11C) respectively compared to that of control HT22 cells. 
However, there is no significant statistical difference compared with that of control cells at any 
time point and only a trend toward significance. 
In contrast, 1.5mM glutamate treatment enhanced the mRNA levels of GCLC in HT22 
cells gradually with a peak of induction observed after 22 hours with P value of 0.02. A 30 
minute pretreatment with AIDA inhibited the rise of GCLC mRNA induced by 22 hr 1.5 mM 
glutamate with P value of 0.03. In fact the level of GCLC mRNA in AIDA treated cells after 22 
hr 1.5mM glutamate was significantly below basal levels (i.e. 70%, Fig 12 A & B).  
The data from GCLM showed a trend of enhanced mRNA levels in HT22 cells treated 
with 1.5mM glutamate after 22 hours without significant difference. There is a significant 
inhibition when we compare the GCLM mRNA level of 1.5 mM glutamate treatment after 22 hr 
to that with a 30 minute pretreatment with AIDA (with a P value of 0.04) (Fig 12 C). AIDA 
alone did not affect the mRNA levels of GCLC and GCLM following 22 hr (D). These results 
provide a potential explanation for the effects of mGluRI activation on the restoration 
glutathione levels in HT22 cells treated with 1.5 mM glutamate.   
 
4.3.2 Effect of glutamate treatment on GCL protein levels in HT22 cells 
At the protein level, 5mM glutamate triggered an increase in GCLC levels that peaks at 1-2 hr, as 
shown by Western blot analysis (Fig 13A). However, GCLM was not affected by glutamate 
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treatment (Fig 13A). Quantitative analysis of GCLC activation in glutamate treated HT22 cells 
from three separate experiments is shown in Fig 13B. A statistically significant two fold of 
activation of GCLC was obtained following a 2 hr 5mM glutamate treatment with P value of 
0.04. The levels of GCLC decreased slightly upon longer exposures to glutamate.  
Consistent with the results from RT-PCR assays, 1.5mM alone induced a gradual rise in 
GCLC protein with a peak observed following 16-22 hr (Fig 14A). Quantitative analysis of 
GCLC activation in glutamate treated HT22 cells from three separate experiments is shown in 
Fig 14B. A 2.8 fold of activation of GCLC was observed following 16-22 hr 1.5mM glutamate 
treatment that was statistically significant with P value of 0.03. 
A 30min pretreatment with AIDA abolished the induction of GCLC protein by 1.5mM 
glutamate and even led to a reduction of GCLC protein levels to below basal line at 22 hr after 
glutamate (Fig 15A). Quantitative analysis of GCLC activation in glutamate treated HT22 cells 
from three separate experiments is shown in Fig 15B. GCLC expression was reduced to 
approximately 30% of basal levels following 22 hr of 1.5mM glutamate treatment with AIDA 
(Fig 15B) with P value less than 0.01. However, GCLM protein levels did not show a similar 
response with glutamate and AIDA (Fig 15A).  
 
4.3.3 Effects of glutamate treatment on Nrf2 expression in HT22 cells 
A 2-8 hr treatment of HT22 cells with 5mM glutamate led to an enhancement of Nrf2 levels as 
revealed by Western blot analysis. However, as shown in Fig 16, the pattern of Nrf2 expression 
was not very consistent (Fig 16). Similarly, Nrf2 protein expression after 10-22 hr 1.5mM 
glutamate with/without AIDA 30 pretreatment shows some variability. It can not be concluded 
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from our results whether the early activation of ERK1/2 contributes to a rebound of glutathione 
levels in glutamate treated HT22 cells through an enhanced stabilization of Nrf2.  
At this point, our analysis of Nrf2 expression is not sensitive enough to prove whether 
Nrf2 is the regulator of GCL transcription in glutamate treated HT22 cells. The inconsistency of 
the results from Nrf2 can not exclude the possible role of ERK1/2 and mGluRI regulation of 
GCL via transcription factors such as Nrf2 or AP1. Further and more sensitive experiments such 
as chromatin-immunoprecipitation (CHIP) assays or electrophoretic mobility shift assay (EMSA) 
may be helpful to verify Nrf2’s role in glutamate-induction of GCL transcription. Specifically, 
CHIP assay may visualize factors bound to the GCL promoter in native chromatin in cells and 
EMSA can quantify the DNA binding activity of GCL promoter factor in extracts. The 
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Figure 11. The GCLC and GCLM mRNA levels in glutamate treated HT22 cells. 
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The mRNA levels of GCLC and GCLM slightly increased in HT22 cells treated with 
5mM glutamate with a peak around 2hr. There may be a trend towards glutamate induction of 
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Figure 12. Effects of AIDA on glutamate induction of GCLC and GCLM mRNA levels in HT22 cells. 
A 30 minute pretreatment with AIDA significantly inhibited the rise of GCLC (A, B) and 
GCLM (A, C) mRNA induced by 1.5 mM glutamate to levels below the basal expression level of 
HT22 cells (*P<0.05). As a control, AIDA alone did not affect the mRNA levels of GCLC and 
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Figure 13. The GCLC and GCLM protein levels in 5mM glutamate treated HT22 cells. 
GCLC protein levels are upregulated following a 5mM glutamate treatment of HT22 cells 
with a peak around 1-2 hours (A). Autoradiograms from Western blots shown in A and replicates 
were subjected to densitometric analysis and relative GCLC levels were quantified using NIH 
Image (n>=3) (B). About 2 fold of induction was obtained following 2 hr 5mM glutamate 
treatment (*P<0.05). However, GCLM is not modulated by glutamate (A). 
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Figure 14. The GCLC and GCLM protein levels in 1.5mM glutamate treated HT22 cells. 
GCLC and GCLM protein levels in HT22 cells treated with 1.5mM glutamate for the 
indicated times were visualized by Western blot analysis (A). Autoradiograms from Western 
blots shown in A and replicates were subjected to densitometric analysis and relative GCLC 
levels were quantified using NIH Image (n>=3) (B). About 2.8 fold of induction was obtained 
following 16-22 hr 1.5mM glutamate treatment (*P<0.05). However, GCLM is not modulated by 
glutamate (A).  
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Figure 15. Effects of AIDA on glutamate induction of GCLC and GCLM protein levels in HT22 cells. 
GCLC, GCLM and GAPDH protein levels in HT22 cells treated with 1.5mM glutamate 
in the 
analysis (A). Autoradiograms from Western blots shown in A and replicates were subjected to 
presence or absence of AIDA for the indicated times were visualized by Western blot 
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densitometric analysis and relative GCLC levels were quantified using NIH Image (n>=3) (B). 
GCLC expression was reduced to 30% of basal line following 22 hr of 1.5mM glutamate 
treatment in the presence of AIDA pretreatment (**P<0.01) (B). However, GCLM is not 
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Figure 16
M 
glutamate treatment (A). In a separate experiment, Nrf2 protein expression was similar at 
different times i.e. 0.5, 2, 4, 6 and 8 hr after 5mM glutamate treatment (B).         
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. Nrf2 protein levels are not consistently affected by glutamate. 
In one experiment, Nrf2 protein expression was induced following a 2-8 hr 5m
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4.4 DISCUSSION  
4.4.1 GCL change following glutamate-induced oxidative toxicity 
Intracellular de novo GSH synthesis is determined by two important factors, GSH precursors and 
the rate-limiting enzyme in GSH synthesis, GCL. In glutamate-induced oxidative toxicity in 
HT22 cells, the low content of intracellular cystine has been well verified. This thesis explored 
whether glutamate affects GCL expression via mGluRI.  
The de novo synthesis of GSH is regulated at several levels in the cell. In general, the 
consumption of GSH by conjugation or reduction reactions leads to an increased production of 
GSH. In part, the increased GSH production is because of the upregulated activity of pre-existing 
GCL as a result of weakened GSH feedback inhibition (197). In addition, the synthesis of new 
GCL subunits through increased transcription and/or mRNA stability has also been suggested to 
result in the increased production of GSH (139). Comparing the two mechanisms to regulate 
intracellular GSH, the inhibition in GSH feedback inhibition is transient and increased GCL 
synthesis is prolonged. It is widely believed that the increase in GSH levels is an adaptive 
response for the cell by which the cell prepares to defend itself against coming stresses (119). 
The time course studies have provided insights into the kinetics of GCL induction. For 
the catalytic subunit GCLC, 5mM glutamate upregulation occurs at an early phase after 
glutamate exposure, i.e. within 1-2 hr. This occurs at both mRNA and protein level. This result 
confirmed the notion addressed above that the early peak of ERK1/2 activation is protective. 
This neuronal protection works through upregulation of GCLC, increased GSH de novo 
synthesis and subsequent maintenance of base line GSH level.     
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Although both GCL mRNA and protein exhibit a small increase at the early phases of 
glutamate treatment, it didn’t reverse the GSH depletion in HT22 cells caused by 5mM 
glutamate. Oxidative stress generated by high glutamate treatment may be too overwhelming to 
cells. However, at the protein level, 5mM glutamate did not induce a parallel change of GCLM 
and GCLC.  
Some previous reports from other groups have illustrated that in response to oxidative 
stress, alterations in cellular GSH are correlated with GCLC to a greater extent than GCLM (119, 
126). For example, effects of oxidative stress were examined in HBE1 cells, immortalized 
human bronchial epithelial cells from a normal individual, by treatments with 10 μM 4-hydroxy-
2-nonenal (4HNE), 5 μM 2,3-dimethoxy-1,4-naphthoquinone (DMNQ), and 25 μM tertiary-
butylhydroquinone (tBHQ) (119). All three compounds increased the steady-state mRNA levels 
of both Gclc and Gclm but resulted in different induction of GCLC and GCLM proteins. 
Specifically, 4HNE and DMNQ induced changes in GCLM protein at levels that bordered on 
statistical significance. tBHQ had no effect on GCLM protein levels under any conditions. 
However, all three chemicals induced significant induction in GCLC protein levels. In addition, 
all of the three oxidative stress inducers can increase the GCLC:GCLM molar ratio in HBE1 
cells (119). 
Therefore, although oxidative stress increases the steady-state levels of GCLC and 
GCLM mRNA, the magnitude of induction of GCL protein varies between the two subunits, 
which may implicate some form of translational regulation. Together with results from molar 
ratio of GCLC:GCLM studies, it has been suggested that de novo GSH biosynthesis does not 
require equal increases in GCL subunit protein (126). Our results reinforce this idea in glutamate 
induced oxidative toxicity in a neuronal cell line. More interestingly, more recently, study from 
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HepG2/C3A (from human hepatoma) cells has demonstrated the differential up-regulation of 
GCL subunits in response to cysteine deprivation (126).   
1.5 mM glutamate induced a gradual increase in GCL mRNA and protein levels with a 
peak observed at 22 hr. A pretreatment with AIDA, a mGluRI antagonist, inhibited induction of 
GCL. mRNA and protein results are consistent with those from intracellular GSH measurements. 
Therefore, AIDA may promote toxicity through its inhibition of GCL mRNA and protein 
induction and subsequent GSH depletion. Results illustrated here confirmed the neuroprotective 
role of mGluRIs in glutamate-induced oxidative toxicity and provided some possible 
mechanisms.  
4.4.2 The mechanism of ERK1/2 effect to GCL regulation 
The upregulation of GCL under oxidative stress has been well documented. However, the 
signaling pathways responsible are still being characterized. MAPK is one of the targets being 
investigated for a role in oxidative stress induced GCL expression. The role of MAPK in GCL 
activation is cell type and model dependent. For example, the MEK1/2 inhibitor PD98059 
completely inhibited the activation of GCLC in primary cultured rat alveolar epithelial type II 
(AT2) cells treated with HNE (138).  p38 and JNK pathway inhibitors had no effect on the 
transcription on GCL in the same model (241). However, in human bronchial epithelial HBE1 
cells, PD98059 is ineffective against HNE-mediated induction of GCL (50), which seems to be 
JNK pathway dependent (50).  
Nrf2, a transcription factor, binds to the ARE within the GCL gene and could lead to 
increased GCLC transcription. As summarized by Iles and Liu, upregulation of GCLC/GCLM 
might work through ERK phosphorylation, increased Nrf2 activity and translocation into nuclei, 
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or more ARE binding pathway in oxidative stress induced by HNE (97). So far, there is no direct 
evidence for phosphorylation of Nrf2 by ERK. A recent paper showed that ERK pathway 
contributes to Nrf2 protein stabilization and subsequent transactivation activity in HepG2 cells 
(170). This finding has provided us a reasonable explanation for the effect of protective role of 
ERK1/2, Nrf2 and GCL upregulation in glutamate-induced oxidative stress.  
Other possible factor could not be excluded in regulating GCL activity. For example, 
activated ERK1/2 could upregulate AP-1 binding via its downstream target c-fos. Both human 
GCL subunits contain consensus binding sites for many transcription factors including ARE and 
activator protein 1 (AP-1). AP-1 binding is required for basal and inducible expression of GCLC, 
GCLM and GS under models of tert-Butylhydroquinone (TBH) (259), curcumin (51) and HNE 
treatment (50). Further studies examining AP-1 binding need to be performed to clarify if it is 








5.0  SUMMARY AND CONCLUSIONS 
5.1 ROLES OF ERK1/2 IN GLUTAMATE-INDUCED OXIDATIVE TOXICITY 
ERK1/2 has been well documented to play disparate roles in neurons. In some cases, ERK1/2 
promotes cell survival, while it also can participate in neuronal cell death and the pathogenesis of 
neurodegenerative diseases. In this thesis, we have demonstrated both prosurvival and pro-death 
activities of ERK1/2 in one neuronal cell line exposed to a single toxic stimulus, i.e. glutamate-
induced oxidative toxicity in the mouse hippocampal cell line, HT22 cells.  
In this thesis, I showed that rapid activation of ERK1/2 by glutamate in HT22 cells is 
driven by type I metabotropic glutamate receptors (mGluRIs). Furthermore, mGluRI activation 
of ERK1/2 represents a cellular adaptive response and defense system that attempts to control 
glutathione loss resulting from glutamate induced cysteine depletion. This protective response 
mediated by ERK1/2 is however unable to overcome an overwhelming and prolonged oxidative 
stress that utilizes ERK1/2 in its final stages to promote neuronal cell death. Thus, ERK1/2 
activation may serve opposing roles in neuronal oxidative toxicity acting initially through effects 
on glutathione metabolism to limit oxidative stress, but serving as a necessary signal to trigger 
cell death when cellular defense against oxidative stress is exhausted.  
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5.2 LOCATION, DURATION AND INTENSITY OF ERK1/2 ACTIVATION 
AFFECTS ITS ROLE IN CELL TOXICITY 
This thesis also supports the hypothesis that the intensity and duration of ERK1/2 activation is 
crucial in determining whether it serves a beneficial or detrimental role in neuronal oxidative 
stress.  
Neuronal cell function is also dramatically influenced by the subcellular localization of 
activated ERK1/2. It has been reported that sustained nuclear localization of ERK1/2 is critical 
for long-term potentiation (181), differentiation (36) and cell injury after hypoxia and ischemia 
(245) in neurons. In addition, it is noteworthy that the subcellular localization of ERK1/2 is also 
critical to trigger glutamate-induced oxidative toxicity in HT22 cells. Because ERK1/2 substrates 
are found in various subcellular compartments (75), the biological outcome of ERK1/2 activation 
will depend in part upon the localization of ERK1/2 and its accessibility to potential targets 
within that compartment  (34, 186).  
Previous results from our groups have established that ERK1/2 translocation into nuclei 
is necessary for glutamate toxicity in both HT22 cells and primary cortical neurons (132, 225). 
Specifically, indirect immunofluorescence staining showed nuclear staining of HT22 cells 
following 5mM glutamate addition (225). Results presented in this thesis also confirmed this 
hypothesis using a sensitive, quantifiable assay of ERK1/2 function in the nucleus. Given that 
ELK-1 is an established nuclear target of ERK1/2, enhanced transactivation activity resulting 
from its phosphorylation by nuclear localized ERK1/2 is easily monitored through the activity of 
a luciferase reporter. In this system, luciferase expression is controlled by the activation of an 
Elk-1-GAL4 fusion by active-ERK1/2 in the nucleus. The results showed that GAL-4UAS-
luciferase activity was induced nearly 2 fold with a 7h 5mM glutamate treatment.  
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Furthermore, the neuroprotective effect of the mutant ERK1/2 phosphatase, MKP3 
C293S mutant transfection, which enhances ERK1/2 phosphorylation but blocks its nuclear 
translocation, demonstrates the necessity for active ERK1/2 nuclear retention for oxidative 
toxicity in neurons (132). MKP3 C293S, a catalytically inactive mutant of MKP3, retains the 
ability to bind to ERK1/2 and therefore functions as a dominant negative to limit the access of 
endogenous ERK1/2 to phosphatases (132). Previous work from our lab has established the 
ability of MKP3 C293S to restrict nuclear translocation of active ERK1/2 in HT22 cells, which is 
consistent with results from a fibroblast cell line (22). MKP3 C293S restricts ERK1/2 
localization to the cytoplasm through its NH2-terminal domain, which can selectively interact 
with ERK1/2 with high affinity. Overexpression of MKP3 C293S can protect both HT22 cells 
and primary cortical neurons from glutamate-induced oxidative toxicity (132). Collectively, 
these results confirmed that glutamate-induced oxidative toxicity in HT22 cells is accompanied 
by the translocation of functional ERK1/2 into the nucleus.  
Therefore, ERK1/2 nuclear translocation and the action of its possible nuclear targets are 
vital to bring about oxidative toxicity in neurons. A variety of ERK1/2 nuclear targets have been 
identified. Some of them are transcription factors such as CREB. Therefore, new transcription or 
translation may be required for the glutamate-induced oxidative toxicity. Some studies using 
transcription/translation inhibitors support this hypothesis. For example, Actinomycin D, a 
transcription inhibitor, prevents the increase in ROS and protects the HT22 cells from glutamate-
induced oxidative toxicity (230). The translation inhibitor, cycloheximide, is also able to protect 
HT22 cells and keeps ROS levels low during glutamate exposure (230). Since in our model, the 
secondary peak of ERK1/2 activation occurs at a time when cells begin to die, there may not be 
enough time for transcription and translation to contribute newly synthesized proteins to cell 
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death pathway. Further studies are needed to clarify the role of ERK1/2 regulated transcription in 
HT22 cell toxicity.  
Results from Chapter 2 also demonstrated that ERK1/2 activation is necessary but not 
sufficient to induce toxicity in HT22 cells. First, overexpression of a dominant negative MEK1 
protein in transfected cells confirmed that ERK1/2 activation is necessary for glutamate-induced 
neuronal toxicity. This molecular tool confirmed results obtained with a pharmacological 
inhibitor of MEK1/2, U0126. Next, we set up a system which induced prolonged ERK1/2 
activation in HT22 cells. Although a 6-fold ERK1/2 activation was generated in HT22 cells by 
overexpression of the MEK-ERK fusions, no cell toxicity was observed. Thus, some other 
factors induced by oxidative stress in HT22 cells must be combined with ERK1/2 activation to 
trigger neuronal toxicity.     
5.3 THE MECHANISM OF DELAYED ERK1/2 ACTIVATION 
The work presented in this thesis demonstrated the opposing roles of ERK1/2 in early and late 
phases following glutamate-induced oxidative toxicity and identified the signal pathway 
responsible for the first peak of ERK1/2 activation, i.e. mGluRIs. The mechanisms of delayed 
secondary peak of ERK1/2 activation are still not fully clear, although ERK1/2-directed 
phosphatase inactivation may play a role in this process (132). In primary immature cortical 
cultures, ERK1/2-directed phosphatase activity is specifically inhibited during the late phase (14 
hr) of glutamate-induced oxidative toxicity, but not in the early phase (1 or 6 hr) (132).  
These results together with data from Chapter 2 suggest a possible dynamic mechanism 
resulting in biphasic ERK1/2 activation. Under glutamate-induced oxidative stress, mGluRIs is 
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initially activated; rapid ERK1/2 phosphorylation and glutathione restoration follow as a cell 
adaptive and self defensive system. Unfortunately, if the oxidative stress is too potent and 
prolonged, such as in the late phase of 5mM glutamate treatment, the mGluRIs are inactivated, 
probably via desensitization. In the meanwhile, selective ERK1/2-directed phosphatase may be 
also inhibited which leads to a late phase of ERK1/2 activation.  
5.4 MGLURIS RAPID DESENSITIZATION 
Desensitization is defined as the tendency of a receptor response to decrease with time after 
exposure to an agonist or ligand (203). It has previously been shown that mGluRI’s protection 
from glutamate toxicity is rapidly desensitized in HT22 cells and primary cultures. For example, 
HT22 cells pretreated with a low dosage (100 μM) of glutamate are much more sensitive to a 
second toxic dose of glutamate that ranges from 10-500 μM) (203). An earlier report has even 
demonstrated that in cerebellar neurons cultures mGluRs desensitization involves, at least in its 
rapid component, activation of PKC (25).  
The desensitization studies also provide the explanation of the biphasic ERK1/2 
activation with glutamate treatment. Loss of ERK1/2 activation following an initial peak may be 
due to desensitization and the late peak of activation may be due to a different mechanism 
excluding mGluR involvement. This explanation is consistent with our previous finding that 
U0126 added after first peak of ERK1/2 activation blocked the late phase of activation and was 
protective.  
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5.5 IMPACT OF GLIA ON NEURON RESPONSE IN OXIDATIVE STRESS 
The majority of the work in this thesis has been performed in the HT22 cell line. Other factors in 
central nervous system, however, need to be taken into consideration if the results presented here 
are to be applied to mechanisms of neurodegenerative diseases.  
For example, growing reports have demonstrated that dynamic and complex interactions 
between astrocytes and neurons secure brain function and survival under both physiological and 
pathological conditions (237).  
As effective sensors of the brain microenvironment, astrocytes react quickly at the 
genomic (e.g., production of beneficial factors) and non-genomic level (e.g., regulation of water 
homeostasis and blood-brain barrier during brain edema and ischemia) (237).  
The mechanism underlying astrocytes’ protection is complex and includes the production 
of various substrates for neurotransmitters (79), transferring energy substrates such as lactate and 
pyruvate to neurons (6), providing metabolites (53) and ions (130) and modulating inflammation 
after ischemia (6). In addition, many factors synthesized and secreted by astrocytes contribute to 
neuronal survival in neurological disorders such as ischemia. These factors are composed of heat 
shock protein (Hsp32) (116), metallothionein1/2 (MT-1/2) (238), thioredoxin (TRX) (92), 
metalloproteinases (MMPs) (40), nerve growth factor (NGF) (129), brain-derived neurotrophic 
factor (BDNF) (236), glial cell-derived neurotrophic factor (GDNF) (257), basic fibroblast 
growth factor (bFGF) (104), neutrophins 3, 4, 5 (NTs) (151) and ciliary neurotrophic factor 
(CNTF) (11) etc. Among them TRX and MTI/II are scavengers of ROS (237).  
A critical role of astrocytes in protecting neuron toxicity induced by oxidative stress has 
been described (216). Astrocytes have stronger potential antioxidative ability than neurons (142, 
145, 192). It is well documented that astrocytes can protect neurons from damage caused by 
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oxidative stress induced by various compounds such as dopamine, H2O2, and 6-
hydroxydopamine and nitric oxide (30, 47, 159).  
The mechanism underlying the antioxidant properties of astrocytes involves their delivery 
of GSH and/or GSH precursors such as cysteine, cystine, and the CysGly dipeptide from glia to 
neurons for GSH synthesis (56). It appears that the Nrf-2-dependent increase in glial GSH 
synthesis is both necessary and sufficient for the protection of neurons.  
Collectively, future studies need to be performed to verify the mechanism shown in this 
thesis in vivo or in neuron-glia co-culture, for example, in primary cortical mixed cultures.  
5.6 NEUROPROTECTION OF MGLURIS IN OXIDATIVE STRESS 
In studies published by Schubert and colleagues (143), glutamate toxicity in HT22 cells was 
found not to be ERK1/2-dependent but driven by JNK and/or p38 MAPK activation. However, 
results from our laboratory and other groups (207) suggest that glutamate toxicity in HT22 cells 
is ERK1/2-dependent. Furthermore, ERK1/2 dependent oxidative toxicity has also been 
confirmed in primary neuron cultures (24) and linked to ischemic cell death in rodent models of 
transient focal ischemia (169).  
In fact, specific agonists and antagonists of mGluRIs have been shown to have anti- and 
pro-apoptotic roles, respectively in HT22 cells and primary cortical neurons (203). As mentioned 
above, contrary to our results, the same group suggested that glutamate induced HT22 cell death 
is not ERK1/2 dependent. In addition, for the past 4 years we have been working with a subclone 
of HT22 cells isolated from a screen of single cell-derived clones with reproducible sensitivity to 
glutamate toxicity. Therefore, it is necessary for us to evaluate the impact of mGluRIs agonists 
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and antagonists on glutamate toxicity in HT22 cells prior to biochemical analysis of role of 
mGluRIs activation on ERK1/2 phosphorylation. 
mGluR-mediated neuroprotection against a variety of toxic stimuli such as ischemia (12), 
nitric oxide treatment (244) and neuropathy in diabetes (16) has been well established. 
Activation of each of the three subgroups can provide protection in the area they express (222). 
MAPK is one of the most common pathways mGluRs function through to display its 
neuroprotective role (222).  
The data presented here provide insight into the mechanisms by which a specific cellular 
signaling pathway, the ERK1/2-MAPK pathway, is recruited during oxidative stress-induced 
neuronal cell death.   
The work in this thesis not only confirmed the neuroprotective role of mGluRIs 
activation in glutamate-induced oxidative stress but also give insights into some mechanisms of 
toxicity. With mGluRI agonist and antagonist, DHPG and AIDA respectively, it has been clearly 
demonstrated that mGluRIs protect cells from oxidative toxicity induced by 5mM and 1.5mM 
glutamate. ERK1/2 phosphorylation at the early phase is one consequence of mGluRI activation 
in our model. Glutathione measurements provided potent evidence that first peak of ERK1/2 
activation protects HT22 cells from oxidative toxicity by upregulation of inreacellular GSH. 
Results from Chapter 3 further illustrated the GCL link between ERK1/2 activation and GSH.  
As discussed in the Introduction, intracellular GSH de novo synthesis is controlled by the 
rate-limiting enzyme GCL. The results presented in Chapter 3 demonstrated the dynamic change 
of GCLC and GCLM in mRNA level (by RT-PCR) as well as protein (by Western blot) in 
glutamate-induced oxidative toxicity. It has been suggested that the restoration of GSH by the 
early phase of ERK1/2 activation is through GCLC modulation. Therefore, effects on precursors 
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and biosynthesis enzymes (GCL) both contribute to alteration in GSH concentration following 
glutamate treatment in HT22 cells.  
Transactivation of the GCL gene may be regulated by transcription factors such as Nrf2 
and/or AP1. Preliminary experiments presented in this thesis are not sensitive enough to prove if 
Nrf2 is the major regulator of GCL transcription in HT22 cells. More sensitive assays such as a 
chromatin-immunoprecipitation (CHIP) assay or electrophoretic mobility shift assays (EMSA) 
may be helpful to verify Nrf2’s role in glutamate-induced oxidative toxicity. For example, the 
CHIP assay can visualize transcription factors bound to promoter in native chromatin in cells, 
while the EMSA measures DNA binding in extracts. These experiments may help to prove if 
binding of Nrf2 to ARE of GCL is upregulated following glutamate induced oxidative stress and 
explore other potential transcription factors binding to ARE of GCL. 
In conclusion, the work presented in this thesis illustrated the opposing roles of ERK1/2, 
i.e. pro-survival and pro-death, in a single cell type. In addition, the mechanism of the 
neuroprotective role of ERK1/2 was revealed. Early phase of ERK1/2 activation, induced by 
mGluRI, aids in protecting the cells against oxidative stress by upregulating intracellular GSH 
level. Furthermore, modulating GCL subunit at transcriptional and translational level has been 
shown to be part of the mechanism of restoration of GSH. However, when the intracellular 
oxidative stress is too overwhelming and prolonged, the late phase of ERK1/2 activation is 
triggered and used as a factor contributing to cell death.  
Studies from our lab have shown that the increased accumulation Zn2+ in neuronal cells 
under oxidative stressed is responsible for the selective inhibition of ERK-phosphatases and 
ensuing ERK1/2 activation and cell death. Interestingly, the late phase of ERK1/2 activation also 
functions to maintain elevated intracellular levels of Zn2+. Thus the elevation of intracellular 
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Zn2+ within damaged neurons can trigger a robust positive feedback operating through activated 
ERK1/2 that rapidly induce Zn2+ dependent cell death. ROS has been considered as an important 
factor triggers the Zn2+ accumulation and following cell toxicity which can explain our previous 
results in Chapter 3 (Fig 6B). Specifically, constitutive ERK1/2 activation alone does not 
promote cell death because ERK1/2 activation itself might not affect Zn2+ release. 
The mechanism of glutamate-induced oxidative toxicity in HT22 cells and the protective 
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